

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problems Mailbox.**

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C12N 15/19, 5/06, 5/08 A61K 35/14, 35/28, 37/02 C07K 15/06, 15/28	A2	(11) International Publication Number: WO 93/09234 (43) International Publication Date: 13 May 1993 (13.05.93)
(21) International Application Number: PCT/US92/09628 (22) International Filing Date: 5 November 1992 (05.11.92) (30) Priority data: 789,169 5 November 1991 (05.11.91) US 931,210 17 August 1992 (17.08.92) US (60) Parent Application or Grant (63) Related by Continuation US 07/931,210 (CIP) Filed on 17 August 1992 (17.08.92) (71) Applicant (for all designated States except US): THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY [US/US]; 857 Serra Street, Stanford, CA 94305 (US).	(72) Inventor; and (75) Inventor/Applicant (for US only): STROBER, Samuel [US/US]; 435 Golden Oak Drive, Portola Valley, CA 94025 (US). (74) Agents: MURASHIGE, Kate, H. et al.; MORRISON & FOERSTER, 755 Page Mill Road, Palo Alto, CA 94304-1018 (US). (81) Designated States: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, PL, RO, RU, SD, SE, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(54) Title: SUPPRESSOR AND PROGENITOR CELLS (57) Abstract Natural suppressor (NS) cells secrete a soluble protein suppressor factor (SF) which suppresses the mixed lymphocyte response. NS cells as described herein are null, i.e., have the phenotype IL-2R ⁺ , CD3 ⁻ , CD4 ⁻ , CD8 ⁻ , TCRαβ ⁻ , Ig ⁻ , MAC-1 ⁻ , or are double negative suppressors (DNS); i.e., have the phenotype IL-2R ⁺ , CD3 ⁺ , CD4 ⁻ , CD8 ⁻ , TCRαβ ⁺ . Both NS and SF are useful <i>in vivo</i> to confer immunotolerance with respect to allogeneic transplants, and to effect immunosuppression. They also enhance engraftment of transplanted cells. A population of cells can be provided using density gradient separation techniques which is enriched in progenitor cells as identified by the presence of CD34 surface markers.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

-1-

5 SUPPRESSOR AND PROGENITOR CELLSTechnical Field

 The invention relates to suppressing immune
response. More specifically, the invention concerns
10 both fresh and cloned natural suppressor cells that
are capable of eliciting immunosuppression in a host,
including suppression of graft versus host disease and
enhancing engraftment of transplanted cells and
tissues. The invention also concerns a soluble
15 immunosuppressive factor capable of suppressing immune
response in response to transplantation or allergens
and in the management of autoimmune disease.

Background Art

20 "Immunotolerance" and "immunosuppression"
are general terms to describe the compatibility of
materials which would be normally expected to result
in an immune response. When tissues or cells are
transplanted into an allogeneic host, absent these or
25 immunosuppressive conditions, the host immune system
will mount an immune response to the foreign antigens
(host-versus-graft disease), and, more seriously, the
immunocompetent cells in the transplant may respond to
the antigens contained in the host (graft-versus-host
30 disease). Other unwanted immune responses include
allergic reactions and autoimmune diseases. Under all
of the foregoing conditions, it is desirable that the
immune response be suppressed.

 It has been known for years that neonatal
35 mammals are capable of acquiring persistent

-2-

immunotolerance with respect to allogeneic immunocompetent cells or to other antigenic substances administered within a few days after birth. For example, mice injected with allogeneic substances bearing the histocompatibility antigens are able later to accept skin grafts from donors of the previously injected genotype. More recently, it has been shown that this immunosuppressive property of neonates is simulated by adults subjected to total lymphoid irradiation (TLI), i.e., high dosages of radiation sustainable when nonlymphoid tissues are protected. Such radiation has been used in the treatment, for example, of Hodgkin's disease. Adult subjects who have been subjected to TLI are also capable of acquiring persistent immunotolerance to antigens administered within a few days of the completion of TLI.

The detailed mechanism by which neonates and TLI-treated subjects are capable of acquiring an immunotolerance with respect to antigens and cells administered within these windows is not understood. Both clonal deletion and active suppression paradigms have been proposed. The picture is further complicated by the presence of at least two types of suppressor cells in neonatal spleens. One type is represented by macrophage precursors, which suppress in vitro the antibody response to sheep red-blood cells. This activity is inhibited by indomethacin, and the cells are thus presumed to be prostaglandin dependent. The other type is represented by lymphocytes which inhibit the mixed leukocyte response (MLR). These cells are apparently prostaglandin independent. One group of cells in this class, "null" cells, lack the surface markers characteristic of T cells, B cells, or macrophages, and have morphologies similar to natural killer cells in that they are large granular lymphocytes which lack antigen specificity

-3-

and which carry out their effective function without antigenic stimulation. The surface phenotype of these cells is Ig⁻, CD4⁻, CD8⁻, CD3⁻, MAC-1⁻, TCRαβ⁻. This population of null suppressor cells has been

5 designated, for purposes of symmetry with natural killer (NK) cells, natural suppressor (NS) cells (Oseroff, A., et al., J Immunol (1984) 132:101).

In addition to the null phenotypes, natural suppressor cells that contain the surface phenotype Ig⁻

10 , CD4⁻, CD8⁻, CD3⁺, MAC-1⁻, TCRαβ⁺ have been recovered from the spleens of adult mice subjected to TLI. These "double negative" suppressors (DNS) can be propagated in vitro under proper conditions indefinitely (Hertel-Wulff, B., et al., J Immunol

15 (1984) 133:2791-2796, incorporated herein by reference). These "DNS" cells can also be cloned from cells obtained from neonatal spleen, normal adult spleen and bone marrow. (The null cells described above have also been cloned from adult TLI spleen and

20 from normal thymus.)

It has now been found that cloned DNS or null cells are capable, when administered in vivo, of suppressing graft-versus-host disease initiated by simultaneously administered immunocompetent cells. In

25 addition, the propagated DNS and null cells secrete into supernatant media a soluble factor which is capable of suppressing the immune response as shown by the ability to suppress alloreactivity in the commonly used in vitro test (the mixed leukocyte reaction (MLR)

30 mentioned above) and in vivo in suppressing the acute immune response referred to as graft-versus-host disease as well as encouraging engraftment of transplanted tissue.

Additional publications of the applicants

35 subsequent to the filing of the parent application herein further describe the cells and secreted factor. The status of the suppressor activity of the NS cells

-4-

in general was reviewed by Strober, S., Ann Rev Immunol (1984) 2:219; a further description of the cloned suppressor cell lines is provided by Schwadron, R.B., et al., J Exp Med (1985) 162:297, and by
5 Schwadron, R.B., et al., Transplantation (1989), p. 107. Hertel-Wulff, B., et al., J Exp Med (1987) 166:1168, describe the rearrangement and expression of T-cell receptor genes in the cloned NS cell lines. The verification of the surface phenotype of the
10 cloned DNS cell lines as IL-2R⁺, CD3⁺, CD4⁻, CD8⁻ and TCRαβ⁺ was described by Strober, S., et al., J Immunol (1989) 143:1118. The DNS cells are thus distinguished from the null NS cells which expresses neither T nor B cell markers (CD3⁻, TCRαβ⁻, Ig⁻). However, both types
15 (null and DNS) express the surface receptor for IL-2 (IL-2R). The null cells are thus CD3⁻, Ig⁻, TCRαβ⁻, MAC-1⁻, and IL-2R⁺. A further description of the soluble factor was provided by Hertel-Wulff, B., et al., J Immunol (1988) 140:2633. A more recent paper
20 by Palathummat, V. et al., J Immunol (1992) 148:373-380 further describes separations of the double negative suppressor cells from bone marrow of murine subjects.

The ability to suppress the capacity of
25 immunocompetent donor cells to effect graft-versus-host disease is of particular significance in view of the growing technology permitting successful allografts and organ transplants. Transfers of healthy tissues into recipients in need of them seems
30 at present limited in the main by lack of immunotolerance with respect to the recipient. Thus, if the problem of graft-versus-host disease could be solved, the dangers associated with bone marrow transplants would be considerably reduced. In the
35 case of whole organ transplants, rejection of the organ would be reduced.

-5-

In addition, encouraging engraftment of transplanted cells is of importance. It is well known that administration of allogeneic tissue in the form of bone marrow to either neonates or adults subjected to TLI during the "window" period will convert the recipient to a chimera, which will recognize as "self" both its own antigens and those of the alloantigen administered at this time. The formation of a chimera shows that engraftment has occurred. The chimeric character of the host is also such that subsequently introduced immunocompetent cells will not attack host tissue. These chimeras are thus not only specifically receptive to the simultaneously administered donor bone marrow, but also to other donor tissue. The chimeric recipient, therefore, will in the future be able to tolerate transplanted tissue from the original donor.

In effecting engraftment, cells enriched in the cell surface marker CD34 are known to be helpful, since this marker appears to characterize "stem" or "progenitor" cells. These cells are progenitors of the multiplicity of differentiated cells that are found in the blood, including monocytes, macrophage, lymphocytes, red blood cells and so forth. Thus, the capacity of transplanted cells to engraft will be dependent on the enrichment of the transplanted cells in cells which bear the CD34 marker.

The recipient normal adult host must, of course, be prevented from succumbing to an acute immune response effected by the originally administered bone marrow cells. The DNS and null NS cells are capable of muting the immediate immune response and any other antidonor response sufficiently to permit the generation of characteristics of the chimera. Both fresh and cloned DNS and null cells are also capable of preventing the in vivo graft versus host immune response. The secreted factor is capable

-6-

of inhibiting the immune response of donor against host, and host against donor cells in vitro, and in vivo.

Both null and DNS cells and the factors
5 secreted by them are therefore useful in providing immediate blocking of either the graft immune response against mammalian hosts or host response to the donor by coadministration of the cells or factors along with
10 foreign substances or tissues to which such immediate tolerance is desired. In addition, and in particular, these cells and/or factors permit the hosts to become tolerant of both present and future grafts where the donor tissue is derived from the same genotype donor as tissue coadministered with the cells or factor.

15

Disclosure of the Invention

The invention provides fresh cells and immortalized cell lines capable of secreting factors useful in suppressing the immune response to any
20 desired antigen, and in encouraging engraftment of foreign cells. The immune response may be that of the host against allogeneic tissue (host versus graft) or that of donor immunocompetent cells to the tissues of the host (graft versus host). The formation of
25 chimeras of the recipient shows engraftment has occurred and permits acceptance of future allografts. Other unwanted immune responses which the cells and soluble factor of the invention are capable of suppressing include allergic and autoimmune responses.

30 Thus, in one aspect, the invention is directed to natural suppressor cells and cell populations containing them, wherein the natural suppressor cells are of two phenotypes. In one phenotype, the "null" phenotype, the surface marker
35 pattern lacks markers characteristic of either B or T cells, as well as macrophage markers. In the "double negative suppressor" (DNS) cell type, the cells lack

-7-

surface markers characteristic of macrophage and immunoglobulins, and also CD4 and CD8 markers characteristic of helper T cells and cytotoxic T cells, respectively. However, DNS cells are CD3⁺,
5 TCR $\alpha\beta$ ⁺, and thus contain these specific markers characteristic of T-cell lineages. Both of these suppressor cell types can be expanded and/or cloned and can be used in the form of cell preparations wherein the suppressive effects of the null or DNS
10 cells are not outweighed by accompanying components of the composition such as CD4⁺ and/or CD8⁺ lymphocytes. The efficacy of the cell composition as a suppressive reagent can be confirmed by its mixed lymphocyte reaction (MLR) "in vitro."

15 These suppressive cells lines and cell preparations are useful in conjunction with bone marrow and organ transplants in preventing graft-versus-host disease (GVHD) and in encouraging the engraftment of the transplanted allografts so as to
20 result in chimeric recipients. The invention is also directed to method to prepare and expand these cell compositions and cell lines, and to their uses in suppression of the immune response, as well as to pharmaceutical compositions containing them.

25 In still another aspect, the invention is directed to a population of bone marrow or blood cells which is enriched in progenitor cells and which can be obtained simply by density gradient sorting of mononuclear white blood cells, and to methods to
30 prepare this population. This population, enriched in CD34 surface marker, is thus obtainable by retrieving the white blood cell mononuclear subfraction of the appropriate density.

35 In another aspect, the invention is directed to a soluble suppressor factor secreted by natural suppressor cells. This factor is useful in various conditions where unwanted immune responses occur.

-8-

Thus, an additional aspect relates to treating these conditions with the soluble factor of the invention and to pharmaceutical compositions suitable therefor.

In other aspects, the invention is directed
5 to recombinant materials and methods for the production of the soluble factor protein and to antibodies and fragments thereof which are specific for the suppressor factor.

10 Brief Description of the Drawings

Figure 1 shows the suppression of MLR by the NS cell supernatants.

Figures 2A-2D show the effect of the stimulated supernatants from TLI-C7 cells on T cell
15 proliferation in the context of MLR and of ConA, PHA and anti-CD3⁺ treatment, respectively.

Figure 3 shows the elution pattern for the soluble factor of the invention from DEAE sepharose.

Figure 4 shows the effect of purified
20 soluble factor on APCs treated with IFN- γ .

Figure 5 shows the response of various bone marrow fractions in the MLR with allogeneic stimulator cells.

Figure 6 shows the ability of various bone
25 marrow fractions to suppress the MLR.

Figure 7 shows the dose response curve for spleen enlargement as a manifestation of graft-versus-host response in neonates.

Figure 8 shows survival rates of mice
30 injected with allogeneic spleen cells with and without NS cells.

Figure 9 shows the elution pattern for the soluble factor of the invention from DEAE Sepharose.

Figure 10 shows the elution pattern for the
35 soluble factor of the invention from lentil lectin.

Modes of Carrying Out the Invention

-9-

The invention is directed to materials and methods capable of immunosuppression in human and other animal subjects. "Immunosuppression" is defined herein as that term is used generally to mean the
5 lowering of an immune response to challenge. While suppression of the response to a particular antigen may be desired, the "suppression" is not so limited. The ability of the soluble factor of the invention to suppress immune response is antigen-independent.

10 "Specific immunotolerance" refers to a characteristic of a host described as the failure of an immune response to occur when a particular target antigen is encountered by either the host or donor material immunocompetent cells. The target antigen
15 may be for example a simple soluble protein or carbohydrate, an infectious cell, or a cell surface. The donor tissue may be an allogeneic transplant tissue which contains immunocompetent cells, in this case the hosts' own tissue are target antigens.

20 "Donor material" refers to a material provided to a recipient to which immunotolerance is desired. The nature of the donor material's immunoreactivity on a molecular level may or may not be known; for example, it may be desirable simply to
25 tolerize a host against allogeneic transplants. In this case, the donor material consists of whatever immunogenic and immunocompetent substances are present in the transplanted tissue.

It is desirable to prevent the response of
30 the host cells to donor tissue (host-versus-graft disease) and of graft-versus-host disease. The latter is accomplished by preventing an immune response on the part of a transplant tissue to the tissues of the host. Under such circumstances, the "donor material"
35 comprises immunocompetent cells which respond to whatever antigenic substances are present in the

-10-

transplant recipient which trigger an immune response by this material.

"Null surface phenotype" refers to the property of one type of the cells of the invention wherein they lack the surface markers characteristic of T cells, B cells, or macrophages, and have morphologies similar to natural killer cells. Thus, they are large granular lymphocytes which lack antigen specificity and carry out their functions without antigenic stimulation. With regard to surface markers, the appropriate surface markers in the murine system include Lyt-1, Lyt-2, and surface immunoglobulins such as murine Ig and Ia. These markers are not present on murine null NS cells. Each mammalian system has its typical corresponding markers, which in the human system includes markers recognized by various monoclonal antibodies known in the art.

In general, generic terminology with regard to surface markers for all vertebrate species will be used; markers typical of T-cell subsets include CD3, CD4, CD8 and CD34; markers typical of immunoglobulins include Ig; markers typical of macrophage include MAC-1. Thus, the null cells derived from any species, including murine and human, are characterized by a phenotype of $IL-2R^+$, Ig^- , $MAC-1^-$, $CD3^-$, $CD4^-$, $CD8^-$, $TCR\alpha\beta^-$. "DNS phenotype" refers to double negative suppressor phenotypes wherein the suppressor cells lack CD4 and CD8 markers. They also do not bear markers for B cells or macrophage. However, these cells are $CD3^+$ (and are therefore T cells) and $TCR\alpha\beta^+$. DNS cells from any vertebrate, including murine and human, are characterized as $IL-2R^+$, Ig^- , $MAC-1^-$, $CD3^+$, $CD4^-$, $CD8^-$, $TCR\alpha\beta^+$. Since they are suppressor cells, they also suppress the MLR in vitro.

"Corresponding" target cells refers to standard assay cells which cytotoxic lymphocytes would

-11-

be expected to lyse. In the murine system, these are YAC-1. In the human system they are K562 cells.

"Cell line" or similar words such as "cells", "cell cultures", and the like refer to the specific genotype described, to its progeny, and to mutants and derivatives thereof which retain the essential characteristics of the original cell. It is well understood that naturally occurring or deliberately induced mutations are common in propagation of particular cell lines, many of which are irrelevant to the desired properties. For example, in the cells of the invention, the ability to suppress the mixed lymphocyte reaction must be retained, as well as the characteristic phenotypic surface patterns for either null or DNS cells, as described above. Other metabolic properties, such as nutritional requirements, antibiotic resistance, and the like are irrelevant to the functionality of the cells, and the definition, as it relates to a particular "cell line", includes mutants and derivatives which contain such alterations. In addition, it is understood to be possible to hybridize two cell lines to retain desired characteristics from both partners, eliminating others. Such hybridomas are considered to be derivatives of the original cell line when the required properties are retained.

In the invention herein, a distinction is made between cloned cell lines and freshly prepared cell cultures which are either or both enriched in a desired population having certain specified characteristics and/or depleted in cells or other components with properties that interfere with the suppressive activity of the null and DNS cells. Bone marrow, thymus or splenocytes are suitable sources of freshly prepared null or DNS cells which can be fractionated, as described below, for example, using Ficoll-Hypaque and/or Percoll gradients. In addition,

-12-

these fractions may be enriched for desired cell populations by supplying suitable growth factors to encourage the proliferation of the desired cells. These freshly prepared, enriched but mixed populations are referred to herein as "fresh" cells. These are distinguishable from the specifically cloned cell lines which can be prepared, if desired, from such "fresh" cells and which are, for practical purposes, a homogeneous population of the same genotype and are either null or DNS cells. Such cell lines may be prepared from any vertebrate source, most usefully, from murine and human sources. Similarly, the suppressor factor of the invention may be prepared using cells from any vertebrate subject.

"Suppresses the mixed lymphocyte reaction (MLR)" refers to the ability of the subject material (soluble factors or cells) to prevent the uptake of a marker substance such as thymidine by maturing T cells in the response which occurs when lymphocytes from allogeneic sources are mixed. Specifically, this property may be tested by the procedure specified according to Hertel-Wulff et al., 1984 (supra), incorporated herein by reference (see below). In general, MLR suppression is species-specific -- i.e., the MLR assay system should be comprised of cells from the same species as the suppressor cells.

"Simultaneous" administration is meant to be approximately contemporaneous, i.e., within several hours.

Activity in the MLR

The NS cells and NS factor protein of the invention are characterized by, and are useful by virtue of, their in vitro or in vivo activities. Their in vitro activity is demonstrated using the mixed leukocyte reaction (MLR), a commonly used protocol to detect alloreactivity. In this protocol,

-13-

lymphocytes from two genetically different individuals of a species are mixed in a culture medium. As the cells of each individual bear different major histocompatibility antigens (MHC) on their surfaces, the T cells of each respond to these differences. The measurement of the response can be simplified by irradiating the cells of one species to permit them to behave only as stimulators of an immune response by the unirradiated (responder) cell population. The immune response is presumed to involve initial secretion of lymphokines by the amplified T cells among the responders, which lymphokines mediate the maturation of cytotoxic T responder cells. This proliferation is monitored by uptake of labeled thymidine ($[^3\text{H}]\text{TdR}$) and suppression of the response is indicated by inhibition of labeled thymidine uptake.

In more detail, in one form of the assay as conducted herein, 5×10^5 normal BALB/c spleen responder cells are mixed with 7.5×10^5 normal C57BL/Ka stimulator cells which have been irradiated in vitro. After 4 or 5 days, the mixed culture is pulsed with $[^3\text{H}]$ -thymidine and thymidine uptake measured after 18 hr. Control cultures typically give $110,000 \pm 7,000$ cpm, and this measure is compared with cpm obtained from cultures to which NS cells or supernatant-containing NS factor had been added, as described below. Both fresh and immortalized DNS and null NS cells, and the soluble factor they secrete, are capable of inhibiting thymidine uptake in the MLR.

Alternatively, the MLR can be measured by assessing the IL-2 secreted into the supernatant. Supernatants are collected and added in serial dilutions to HT-2 cells (10^4 cells/well) in flat-bottom microtiter plates. After 24 hours culture at 37°C , proliferation is measured by the tetrazolium assay (MTT assay) described by Mosmann, T., J Immunol Meth (1983) 65:55, or by thymidine incorporation. For

-14-

thymidine incorporation, 1 μ Ci/well of tritiated TdR (specific activity 6.7 Ci/mmol) is added 4 hours before harvesting the culture on glass filters and the harvested cells are counted in a Beckman Liquid Scintillation Counter. IL-2 concentration is calculated in comparison to titration of standard recombinant IL-2 in the same assay. The ability to inhibit uptake of the thymidine or IL-2 production by responder cells is independent of the antigenic makeup of the stimulator cells and does not require that the haplotypes of the suppressor and responder cells be matched. The mechanism of the suppression is not known, but it has been established that neither IL-2 induced proliferation of HT-2 cells nor IL-1 secretion by macrophages is directly inhibited by the cells or factor of the invention.

Suppression of GVHD

In one assay to assess the in vivo activity for suppression of GVHD, mice which have been irradiated with sublethal dosages of radiation are injected with suspensions of the fresh or cloned NS cells or with the factor, each coadministered with spleen cells or bone marrow derived from an allogeneic species. Subsequent prevention of lethal graft-versus-host disease confirms the immunosuppressive action with respect to the donor cell immune attack on the host. The DNS and null NS cell suspensions and the NS factor proteins are able to suppress the immediate immune response of the immunocompetent donor cells against host tissues.

While the data in these assays show the prevention of graft-versus-host disease--i.e., immunotolerance of donor immunocompetent cells with respect to host tissue, in the case of chimeric hosts it thereby follows that the host's own immunocompetent cells are, in a complementary manner, tolerized to

-15-

allogeneic or other foreign tissue. In addition, these results demonstrate the ability of the cells and factor to generate immediate immunosuppression.

5 Assay for Enhancement of Engraftment

For those recipients receiving bone marrow rather than spleen cells, immunotolerance to later skin allografts where the donor was of the strain from which the bone marrow was derived is achieved in the recipients if engraftment has occurred. These direct experimental results demonstrate the ability of the DNS and null NS cells and the NS factor to permit engraftment. The cells to be transplanted can also be assayed for their potential to effect engraftment by assessing the proportion of cells which contain CD34 surface markers. This assessment can be made using standard techniques such as immunofluorescent staining followed by FACS. The methods of the invention described below provide for enrichment of the cell population in cells with these surface markers.

Preparation of NS Cells

Propagation of spleen cells derived from TLI or neonatal mice is conducted as described by Hertel-Wulff et al., 1984 (supra). Mice were used as convenient subjects, but, of course, other vertebrates could also be used.

Human cells are also available as subject cultures using spleens removed for medical indications from neonates or removed from previously ascertained donors who, for other medical indications, had been subject to total lymphoid irradiation, and are recently deceased. In the alternative, human bone marrow which carries null and DNS surface phenotypes can be used. It has been shown by the present applicant that suppressor cell compositions consisting essentially of DNS cells are readily prepared from

-16-

neonatal spleen, normal adult spleen, adult TLI spleen and bone marrow. Null cells have been prepared from adult TLI spleen and normal thymus.

A variety of separation procedures can be used to obtain the desired cell populations. In general, the cell population is derived from a blood cell source such as bone marrow or blood and represents a low density fraction thereof. The low density fraction, depending on the source, is about less than 10%, preferably less than 5% of the total cells in the blood cell source. The composition of this low density fraction is such that the composition is capable of suppressing the mixed lymphocyte reaction, but preferably is not capable of killing the corresponding target cell population. In order to show these characteristics, this low density fraction must have a ratio of suppressor cells, either or both null NS cells or DNS cells, whose suppressive activity is not outweighed by the immunoactivity of helper and cytotoxic T-cells bearing CD4 and CD8 markers. In addition, this low density fraction may include progenitor cells such as CD34⁺ cells, or may be supplemented with such progenitor cells. The precise manner of preparing the low density fraction will vary with the source of blood cells and the desired application. However, in general, gradient separation based on cell density is employed. By routine optimization, it is possible to establish precise density gradient fraction limits in g/ml for the desired fraction. The correct characteristics for the isolated fraction may then be established by demonstration of the ability of the fraction to suppress the MLR and, if desired, to fail to show cytotoxicity to corresponding target cells.

For example, isolation of a suppressive cell composition from mouse bone marrow can be conducted by treating a suspension of cells from murine bone marrow

-17-

with a Percoll gradient and obtaining the gradient fractions. Recovery of the low density fraction representing about 5% of the total starting cells represents an effective suppressive composition.

5. Similarly, human bone marrow may be subjected to fractionation using a combination Ficoll/Hypaque gradient (to remove polymorphonuclear cells), starch treatment to remove red blood cells, plastic adhesion treatment to remove monocytes, and so forth, in conjunction with subjecting the cells suspension to a Percoll gradient and recovering the low density fraction containing roughly 5% of the starting material, similarly to the procedure with regard to murine cells. Preparation of these fresh cell compositions from human bone marrow involves a few additional steps designed to deplete certain types of cells from the compositions.

The fresh cells can be more finely sorted by subjecting the suspensions to preliminary fractionation followed by flow cytometric techniques to recover specifically cells which are DNS or null by virtue of their surface markers. In this procedure, the cells are selectively stained with regard to the desired surface features and sorted accordingly.

- In one illustrative procedure, if bone marrow is used, the null lymphocyte population can be isolated using standard gradients such as Ficoll-Hypaque or Percoll and cultured in standard tissue culture media with the addition of an appropriate lymphokine such as IL-2 or the supernatant from human peripheral blood lymphocytes stimulated with PHA. The null and DNS phenotypes are propagated as a polyclonal population, and then colonies are analyzed for suppressive activity using a human mixed lymphocyte reaction (MLR) similar to that described for the murine cells herein. The isolated phenotype resembles that described herein for the murine system. In

-18-

addition to suppressing the appropriate MLR, the cell has a null or DNS surface phenotype and no natural killer function--i.e., it is not able to lyse human tumor K562 cells.

5 Verification that an appropriate population has been obtained is provided by the ability of the composition prepared to suppress the MLR *in vitro*. . Provided the appropriate enrichment/depletion has occurred in the preparation, and the appropriate
10 phenotype is ascertained, *in vitro* suppression of the MLR provides a showing that the composition is of sufficient purity to have the desired suppressive effect *in vivo*.

 In addition, the population has reduced or
15 no ability to kill the corresponding target cells, such as YAC-1 for mice or K562 for humans.

 In addition to preparing enriched/depleted populations by fractionation, the desired cells can be expanded using cytokines such as IL-2, PHA, or ConA,
20 alone or in combination.

 In one typical procedure illustrative of the general approach, wherein the murine system is exemplified, spleens were removed aseptically either from newborn BALB/c mice (1-14 days old) or mice which
25 had been subjected to TLI. In the irradiation procedure, 4-6 month old male BALB/c mice were anesthetized daily with pentobarbital and were positioned in an apparatus designed to irradiate the major lymphoid organs (lymph nodes, spleen, and
30 thymus) described by Slavin et al., J Exp Med (1977) 146:34; skull, lungs, tail, and hind legs were shielded. The mice were given 200 rad/day 5 times a week for a total dose of 3,400 rad, using a dose rate of 92 rad/min with a 0.35 mm copper filter and a 52 cm
35 source/axis distance. Tetracycline was added to the drinking water during TLI and for one week after

-19-

completion of radiation. TLI-treated mice were sacrificed between 1-3 days after completion of TLI.

Single cell suspensions were prepared by incising the capsule and disrupting the splenic parenchyma. The suspended cells were cultured in RPMI-1640 containing 25 Mm HEPES, 2 Mm glutamine, and 5×10^{-5} M 2-mercaptoethanol, with 10% fetal calf serum (FCS) and 10% supernatant from Concanavalin A stimulated rat spleen cells (CAS). CAS was prepared as described by Oseroff, A. et al., J Immunol (1984) 132:101-110. Aliquots of 1.5×10^6 cells per well were placed into 24-well plates, and aliquots of 5×10^6 cells were placed in small flasks. In some cultures 5×10^5 TLI-treated cells were incubated with 1×10^6 spleen cells irradiated with 1500 rads in vitro, as feeder cells, and fresh feeder cells were added every 10-14 days for the first 2-3 weeks. Cultures were fed with 10% CAS-containing medium every 2-3 days for the first 2 months, at which time the cultured cells grew slightly adherent to the plastic surface. Cultures were then fed every day and maintained in vitro for at least 48 months. After 8 months in cultures, the cells were cloned using limiting dilution by seeding using 1.5-5 cells per ml in complete medium supplemented with 10% CAS.

The cloned cells were moderately large with granular and vacuolated cytoplasm. These cell lines, one obtained from neonates and designated 4BA4, and two others obtained from TLI mice and designated TLI-C7 and TLI-2.4C were used for further study.

In a completely analogous manner, populations of suppressor cells from other species are stimulated and expanded. Human suppressor cell populations prepared from, for example, spleen, thymus or bone marrow are expanded using similar steps.

Both types of murine NS cells are not able to lyse YAC-1 tumor cells; human NS cells do not lyse

-20-

K562 cells. However, of course, they suppress [³H]TdR uptake in the MLR.

Enrichment in CD34+ Cells

5 It has also been found possible to enrich
the cell population derived from a mammalian blood
cell source for progenitor cells as indicated by the
presence of the marker CD34 in humans. An enrichment
in such progenitor cells is useful in situations
10 wherein autologous stem cells need to be transplanted
into subjects to restore stem cell activity, as well
as in allogeneic transplants. For example, patients
who have tumors treated by lethal doses of
chemotherapy and/or radiation, such as those with
15 breast, ovarian, or myeloma type cancers cannot
survive the treatment without restoring their
hematopoietic progenitor cell systems. Generally,
this is done by administering cells from the patient's
own bone marrow. The bone marrow is subjected to
20 treatment to remove the white blood cells and these
are frozen. It has also been possible to obtain
sufficient progenitor blood cells from the peripheral
blood of patients who have been treated with G-CSF.
However, while use of blood is more convenient in
25 terms of patient comfort, the number of white blood
cells which would include these progenitor cells, as
prepared by leukaphoresis and required for storage is
inconveniently large. Storage is effected in the
presence of DMSO, which may not be completely removed.
30 Further, there have been problems with contamination
with the patient's tumor cells; the large number of
cells stored makes purging impractical.

These problems have been avoided previously
by passing the white blood cell preparation obtained
35 from blood over a column containing anti-CD34
antibodies and freezing only the adherent CD34⁺ cells.
However, the columns are not reusable and are costly.

-21-

In the method of the invention, a concentrated portion of the blood or bone marrow containing an enriched population of CD34⁺ cells can be obtained, without the necessity of using an expensive affinity column, by gradient density separation. It has been found that under conditions previously used for gradient separation of human hematopoietic progenitor cells, wherein precautions have not been taken to confine the progenitor cells to a small fraction (<5%) of the total cells subjected to separation and to adjust the ionic strength to that of physiological salt, satisfactory enrichment and yields cannot be obtained. According to the method of the invention, gradients are employed wherein ionic strength corresponding to physiological salt is ensured, and gradients are prepared such that at least 50% of progenitor cells in the original cell population are recovered in a narrow density range which accounts for <5% of cells obtained from the gradient.

In one exemplary approach, rather than the conventional use of 1 part 10X physiological saline to 9 parts Percoll to prepare a stock solution for further dilution in physiological salts for gradient formation (even with pH adjustment to physiological pH) gradients obtained by further diluting the stock with RPMI have been unsuccessful in providing fractions enriched in the desired progenitors. According to the method of the invention, a dilution of 1 part 10X physiological saline to 12 parts Percoll, with pH adjustment, is one workable embodiment whereby preparation of a stock solution at physiological salinity can be assured. Subsequent dilution of the stock with, for example, 50-60% of a solution corresponding to physiological salt such as RPMI or Ringer's solution in 2.5% discontinuous steps then results in a satisfactory gradient.

-22-

The invention method thus results in a gradient separation conducted at the ionic strength and osmolality of physiological salt. The 12:1 ratio of Percoll to 10X physiological salt results in a stock which is, itself, at physiological osmolality. This alters the size distribution of cells as compared to prior art conditions, which exceed physiological osmolality.

In a typical preparation, the manufacturer's directions for preparing a gradient are followed, except that the required 12 Percoll:1 10X physiological saline dilution with a 10X concentration physiological saline is employed to obtain the stock solution and the pH adjusted to physiological pH. The resulting osmolality of this stock Percoll is 280-290 mOms; corresponding to that for humans. According to the typical dilution of 9 parts Percoll:1 part 10X physiological saline ordinarily used to obtain stock, osmolalities of 310-320 mOms are obtained.

With the appropriate dilution of Percoll stock, a conventional gradient using 50-60% dilutions of a solution corresponding to physiological salt in 2.5% discontinuous steps and separation according to the gradient results in a satisfactory provision of the required enriched fraction.

In general, the enriched population constitutes the lowest density portion of the gradient representing 5% or less of the cells subjected to the gradient, preferably 3% or less.

However, there is considerable variation from patient to patient, and the fractions should be assessed for surface markers using known techniques. For autologous transplants, it is necessary only to assay the levels of the CD34 marker to assure that a sufficient percentage of the cell population is, in fact, progenitor cells. For allogeneic transplants, however, it is also helpful to assure that the CD4⁺,

-23-

CD8⁺ population is sufficiently depleted that graft-versus-host disease does not occur. In some instances, even though the fraction which resides in the 45-47.5% Percoll gradient illustrated below often
5 contains substantial amounts of CD34⁺, the T-cell population may trail into this fraction and make it undesirable for use in allogeneic transplants. In autologous transplants it is clearly undesirable to deplete the T-cell component completely, since the
10 graft-versus-leukemia response and engraftment will be inhibited. In allogeneic transplants, the necessity for these cells remains, but the presence of the suppressor cell populations of the invention in these fractions offsets the ability of these T-cells to
15 mediate graft-versus-host disease.

The density gradient is generally conducted on cells that have been depleted of red blood cells and/or polymorphonuclear cells. Thus, cells from blood or bone marrow are first subjected to
20 sedimentation in heta-starch solution to remove red blood cells and a Ficoll gradient for removal of polymorphonuclear cells prior to subjecting them to the Percoll gradient. Alternative methods for this removal comprise centrifugation to remove red cells.
25 The cells are then subjected to Percoll gradients and the hematopoietic progenitor cells are enriched 10-20 fold in the fractions of 40-45% Percoll; the total number of cells in these fractions represents only about 5% of the original cells in the blood cell
30 source and in general, at least 50% of the original hematopoietic progenitor cells (CD34⁺) can be recovered.

The recovered fractions can be assessed for a satisfactory population of progenitor cells by
35 determining the presence or absence of the CD34 marker. Typically, at least 10% of the cells in the

-24-

recovered fraction, preferably 15%, and more preferably 20% will bear the CD34⁺ marker.

The recovered fraction can then be stored and used for stem cell replacement in subjects requiring this treatment.

Preparation of the Soluble Factor

The suppressor cell lines of the invention can generally be derived and cultured as described above. They can be further immortalized by fusion to immortalizing cell lines, infection with virus, or other means known in the art.

The soluble factor is produced from the expanded, immortalized or cloned cells by suitable inducing conditions, which include those particular conditions specified above, as well as addition of other materials which stimulate the phosphatidyl inositol pathway to the medium. The supernatants containing NS cell-secreted factor may be used per se, or may be subjected to purification techniques as described below to isolate the factor with the suppressor activity by tracking active fractions as measured by suppression of the MLR.

Thus, the suppressor cells of the null or DNS phenotypes may be induced to produce the soluble suppressor factor by addition of suitable inducing agents. One effective class of such agents includes those which activate the phosphatidyl inositol pathway, such as the phorbol esters. For example, secretion of the NS factor is stimulated by the addition of 5-20 ng/ml of PMA and 0.05-1.0 µg/ml of a calcium ionophore to the medium.

Similar conditions are used to stimulate suppressor factor production from any mammalian cell cultures, including human.

The suppressor factor from the murine cells exemplified has been partially characterized. The

-25-

analogous factor from cells of other mammalian species, including humans, has similar properties. First, it has been verified that the supernatants of the isolated cell lines are free of activity exhibited by IL-1, IL-2, IL-4, IL-6, IL-7, and IL-10. The supernatants do contain IL-3, GM-CSF tumor necrosis factor- α (TNF α), TGF- β , and γ -interferon activity. However, the suppressor factor has been shown not to be identical to these. With respect to IL-3, recombinant IL-3 does not show suppressive activity in the standard MLR. Recombinant γ -interferon does not show such activity when IL-2 secretion is used as a measure of MLR. After removal of all γ -interferon from the supernatant by immunoaffinity chromatography, the suppressive activity of the supernatants is retained.

Initial chromatographic separation on Sephadex G-150 of the proteins from the media in which the cells were cultured showed 90% of the suppressor activity in the two peaks of 135 kd and 240 kd. These peaks are removed from the peaks associated with elution of the major proteins in the media. In an exemplary procedure, 650 μ l of the supernatant is loaded onto a Sephadex G-150 column and eluted in pyridine:acetic acid buffer or PBS buffer at pH 7.2. The eluate is collected in 500 μ l aliquots using size markers.

The specific activity of the pure suppressor factor is high, as the protein profiles on the Sephadex column appear identical for induced and noninduced cells; however, only the 135 kd and 240 kd peaks from the induced cultures show suppressive activity. These peaks are believed to represent multimers of the SF of the invention.

The partial purification of the suppressor factor (SF) from the TCI-C7 line is described in Example 3 hereinbelow. Briefly, the supernatant is

-26-

first concentrated and then chromatographed on a DEAE-Sephacrose column and eluted in a sodium chloride gradient. The fractions containing the MLR suppressing activity are pooled, concentrated and dialyzed and further purified on a lentil lectin column. A lentil lectin Sepharose 4B column may conveniently be used and the dialyzed fractions are applied in buffer at pH 8.0. The column is eluted with a linear gradient of a carbohydrate known to bind said lectin, preferably α -methyl-D-mannoside. The fractions assayed to suppress the MLR are then pooled and subjected to electrophoresis under nonreducing conditions using SDS-PAGE. An approximately 20 kd band is detected by silver staining and the corresponding position is eluted and the recovered protein is able to suppress the MLR. Alternatively, the fractions from the lentil lectin column which exhibit activity can be sequenced directly. The N-terminal sequence of the eluted protein is: X-Glu-Asn-Val-Gly-Leu-Asn-Glu-Val-Val-(Ala/Phe)-Leu-(Lys/Leu)-Tyr-Gln-Val. The amino acid at position 1 could not be determined definitively.

Antibodies are raised to the peptides Leu-Asn-Glu-Val-Val-Ala-Leu-(Lys/Leu)-Tyr-Gln-Val by immunization protocols in suitable mammalian hosts, typically rabbits. The antisera obtained are able to remove the suppressive effect of the supernatant from PMA/ionophore-stimulated supernatants of TLI-C7 cells in the MLR after solid-phase immunoadsorption. Further, these antibodies immunoreact with the 20 kd band on the SDS gel.

The antibody preparation is then conjugated to a solid support and can be used for affinity purification of SF from the stimulated supernatants.

-27-

Recombinant Production of the Suppressor Factor Protein

The suppressor factor protein of the invention may be isolated from cells or cell lines after appropriate stimulation with PMA/ionophore or may be produced using recombinant means from a variety of hosts. The N-terminal amino acid sequence set forth above is used to design suitable probes for recovery of DNA encoding the SF protein from DNA libraries. Suitable DNA libraries may be prepared from genomic DNA, or, more preferably, as cDNA libraries by reverse transcription of mRNA isolated after stimulation with PMA/ionophore from cells or cell lines capable of secreting said SF protein. The library of choice is then probed using standard hybridization conditions with the degenerate probe mixture designed based on the amino acid sequence set forth above. Alternatively, expression libraries may be prepared using, for example, λ gt11 in E. coli and the protein produced by transformants containing DNA encoding the SF detected by immunoreactivity with antibodies which have been prepared by immunizing subjects with the SF or peptide fragments thereof and recovering the antisera.

The encoding DNA is then sequenced to confirm its correspondence to the SF amino acid sequence and ligated into an expression system for transformation into a suitable host. The recovered DNA is also used as a probe to recover the DNA encoding the corresponding SF protein from libraries prepared from other mammalian species, such as the human SF.

A wide variety of expression systems applicable to both procaryotic and eucaryotic hosts is now available, some expression systems, indeed, being available commercially. Thus, suitable expression systems are available for production in E. coli or

-28-

other prokaryotes, in yeast, in insect cells based on a baculovirus expression system, in mammalian cells, and in plant cells. The choice of appropriate host will depend on the desired form of the SF protein as determined by the posttranslational processing capabilities of the cells selected.

The transformed host cells are then cultured under conditions which favor the expression of the encoding DNA, and the SF protein is recovered from the culture. The expression system may be designed so as to effect the secretion of the SF; in this circumstance, the SF is purified directly from the supernatant. Alternatively, the SF may be produced intracellularly, in which circumstance lysing of the cells is required prior to protein purification. The protein is then purified using standard methods such as gel filtration, chromatography, adsorption chromatography, SDS-PAGE, and the like.

The recombinantly produced SF is advantageous in that it can be provided free of any danger of contaminating infectious agents and the level of production can be controlled and elevated relative to cellular proteins so that the purification of the SF is simplified.

25

Preparation of Anti-SF Antibodies

The SF protein of the invention may be used in standard immunization protocols to generate antisera containing antibodies specifically immunoreactive therewith, and peripheral blood cells and splenocytes which may be immortalized to provide sources for monoclonal antibodies immunoreactive with the SF. The SF, or a selected peptide fragment thereof, is administered under standard immunization protocols and adjuvant regimens to suitable hosts such as rabbits, rats, mice and the like. The antisera or antibody-producing cells are recovered using standard

-29-

techniques. The antibodies thus obtained are useful in assay systems to determine the presence or level of SF in biological fluids.

5 Administration and Use

 The NS cells either null or DNS and induced supernatants as well as the SF protein per se of the invention will be useful in conferring immunosuppression and immunotolerance on a host
10 subject. Subjects susceptible to this treatment include any vertebrate species, including human, but particularly the NS cells and SF protein compositions are adaptable to use in mammals. The conferred immunosuppression or immunotolerance is especially
15 useful in permitting the host to accept simultaneous or future transplants of tissues or cells from an allogeneic donor. Also, since the suppression is not antigen-specific, subjects with unwanted immune responses to allergens or autoantigens will benefit
20 from administration of the cells or SF protein. Thus, for example, these medicaments are useful to treat autoimmune diseases such as rheumatoid arthritis or myasthenia gravis.

 The dosage levels required are highly
25 dependent on the nature of the host and on the nature of the immunological challenge. However, as an overall estimate, in the method of the invention, the NS cells are administered to the host receiving autologous donor material will be in the amount of
30 approximately 10^8 - 10^{10} cells/kg of host weight, along with a comparable number of cells to be used in the allogeneic transplant. The amount of SF protein administered is comparable, i.e., the amount produced in the supernatant from about this same number of
35 induced cells. Coadministration with similar numbers of foreign immunocompetent cells permits contemporaneous acceptance of these transplants.

-30-

In addition, the foregoing treatment may be used in conjunction with subsequent implantation or injection of tissue from the same donor which has been co-injected with the NS cells or the protein factor, as above. The initial simultaneous administration may use immunocompetent donor tissue, or donor bone marrow or the bone marrow hematopoietic stem cells.

For allogenic transplants, the suppressor cells are preferably derived from the donor in the case of bone marrow transplants, and from the recipient in the case of organ transplants. For use in treatment of autoimmune disorders, the patient is used as the source of the suppressor cells.

The cell populations of the invention which are enriched in CD34+ stem cells are useful both in allogenic and autologous transplantation protocols. While in autologous transplantation suppressor functionality is not required, capability to engraft is extremely important. Thus, the cell populations obtained by the method of the invention which have high populations of CD34+ cells as compared to unsorted populations are helpful in encouraging the success of the transplant both in allogenic and autologous protocols. The source of the stem cells is generally bone marrow although blood can be used provided the subject has been treated with stimulating factors such as G-CSF to enrich the blood in these cells. Treatment with G-CSF, for example, often results in a tenfold enrichment of hematopoietic progenitor cells in the blood. The enriched progenitor cell population obtained by density gradient sorting under suitable physiological conditions as described herein can be stored as a subfraction of the blood or bone marrow until needed for subsequent use.

With respect to the cell populations used in connection with transplantation, techniques for

-31-

administration of these cells as portions of the transplant are well understood by the practitioners of the transplantation art. A variety of techniques using straight forward medical procedures is
5 available.

With respect to treatment for immune suppression per se, administration is typically by injection, either intravenous (especially for the soluble factor) or intraperitoneal (which is preferred
10 for the NS cells). However, other modes of administration, such as oral, transmucosal, or using other formulations as is understood by those in the art may also be used.

Pharmaceutical compositions of SF may be prepared using standard formulation techniques suitable for the mode of administration. Suitable formulations may be found, for example, in Remington's Pharmaceutical Sciences, latest edition, Mack
15 Publishing Company, Easton, PA. In general, the SF active ingredient is supplied at 0.5%-90% of the
20 formulation and suitable excipients, such as buffers, stabilizers, carriers and the like are added. For particular routes of administration, excipients with additional functionalities such as penetrants or
25 detergents may be required.

Suitable subjects for administration of the SF protein of the invention include vertebrates, in particular mammals, including humans in need of immunosuppression. In general, such individuals
30 include those afflicted with autoimmune conditions such as rheumatoid arthritis, myasthenia gravis, juvenile diabetes, lupus erythematosus, multiple sclerosis, and the like. Another major group of suitable recipients includes those with hyperimmune
35 responses to allergens. Still another group includes those who are recipients of transplanted tissues such

-32-

as kidneys, lungs, heart, bone marrow, skin, and the like.

The subject matter of the invention further includes antibodies immunoreactive with the suppressor factor of the invention. These antibodies are useful in assessing the amounts of suppressor factor present in a biological fluid. Such assessment can be made by standard immunoassay procedures as is well known in the art. Thus, both direct and competitive immunoassays may be used; the antibodies may be labeled, conjugated to solid support, or otherwise modified to render their use in these methods more convenient. Variations on immunoassay protocols suitable for use in the present invention are well known in the art.

The following examples are intended to illustrate but not to limit the invention.

20

Example 1

Suppression of MLR

by Cloned NS Cells and Supernatants

Both the NS cells and their induced supernatants were capable of suppressing the MLR conducted as follows: Responder cells (5×10^5) and stimulator cells (7.5×10^5) were incubated with graded numbers of the NS cells in 0.3 ml/wells in 96-well microculture plates. The culture medium was supplemented with 2 mM glutamine, 5×10^{-5} M 2-mercaptoethanol, 100 units/ml penicillin, 100 μ g/ml streptomycin, and 10% pooled human serum (VSP, Biocell Laboratories, Carson, California). The NS cells and stimulator cells were given 3300 rad before incubation. Cultures were maintained at 37°C in 5% CO₂ for 5-6 days. Eighteen hr before termination, 1/ μ Ci of [³H]TdR (6.7 Ci/mM) was added to each culture. Cells were harvested with a semiautomatic

-33-

cell harvester and counted in a Beckmann liquid scintillation counter.

Three illustrative cell lines cultured from the spleens of TLI mice, designated TLI-2.B7 (DNS),
5 TLI-2.H5 (null), and TLI-2.4C (DNS), suppressed the MLR significantly at co-cultured cell counts of 2×10^4 per well. Suppression in the range of 90% was obtained at this concentration when C57BL/Ka stimulator and BALB/c responder cells were used.
10 Similar results were obtained with A/J responder and C57BL/Ka stimulator cell lines.

Suppression of the mixed lymphocyte reaction was also obtained when supernatant from TLI-2.4C (DNS) cells was added to the cultures (controls give $110,000 \pm 7,000$ cpm).
15 Figure 1 shows the data obtained in the MLR comparing the result for added supernatant with and without induction.

Supernatants were obtained from cloned TLI-2.4C cells 24 hr after they had been induced with
20 10 ng/ml PMA (4-phorbol-12-myristate-13-acetate) and 0.26 μ g/ml A23187 calcium ionophore for 4 hr at 37°C/5% CO₂. When dilutions of this induced supernatant were added to the MLR, a 75% suppression of the MLR was obtained using a 1:5 dilution of the
25 supernatant. Uninduced supernatant gave only a 40% suppression at this dilution. The results are more clearly seen at a 1:10 dilution, where the induced supernatant gives a suppression of 55% while uninduced supernatant shows a 30% stimulation of the reaction.

30 The activity of the induced supernatant is destroyed by pronase treatment and is associated with a dialysate of >20 kd.

-34-

Example 2Effect of Supernatants from Cloned Activated NS Cells
on IL-2 Production

The supernatants were obtained from the TLI-
5 C7 (DNS) clone derived from the spleen of an adult TLI
mouse (given total lymphoid radiation), as described
by Hertel-Wulff, B., et al., J Immunol (1984) 133:2791
(supra). The clone has been verified to have the
surface phenotype CD3⁺, CD4⁻, CD8⁻, TCRαβ⁺ as set forth
10 by Strober, S., et al., J Immunol (1989) 143:1118.
The stimulation of these cells with PMA and A23187 was
as described by Strober, S., et al., J Immunol (1987)
138:699. Briefly, the TLI-C7 cells were grown to
confluence in T-75 flasks and PMA (10 ng/ml) and
15 A23187 (0.26 μg/ml) dissolved in RPMI-1640
supplemented with 10% heat-inactivated FCS, was added
to the TLI-C7 cells in a final volume of 20 ml/flask.
After incubation for 4 hours, the cells were washed 5x
with PBS and overlaid with RPMI-1640 containing no
20 additional proteins. The supernatants, referred to
later in this example as IC7, were collected 24 hours
later and kept frozen at minus 40°C until use. PMSF
was added to the stored IC7 to a concentration of 0.1
mM to prevent protease degradation.

25 The mixed lymphocyte reaction (MLR) was
conducted as described above, except that in lieu of
thymidine uptake, IL-2 production was measured as
described hereinabove. The results are shown in
Figure 2A. In a control reaction, when responder
30 cells were used alone, no IL-2 was secreted (open
circles). When the standard MLR is conducted with the
addition of the stimulator splenocytes, IL-2
production reaches a peak of 6 IU/ml after 96 hours
(open squares). However, in the presence of a 1/5
35 final dilution of IC7, suppression of IL-2 secretion
is clearly shown, reaching a maximum of only 1 U/ml

-35-

after 72 hours and decreasing thereafter (open triangles).

It has been reported previously that TLI-C7 cells stimulated with PMA and A23187 secrete TGF- β , GM-CSF, TNF- α , and IL-3, but not IL-1, IL-2, IL-4, IL-6, IL-7 or IL-10 (Van Vlasselaer, P., et al., Cell Immunol (in press), incorporated herein by reference). The cytokines whose secretion had been demonstrated were added to the standard MLR assay in concentrations ranging from 1000 to 0.5 U/ml (IFN- γ , IL-3, GM-CSF, TNF- α) or 10 to 0.05 ng/ml for acidified TGF- β . The concentrations reflect the level at which the cytokines were detected in IC7. IL-2 concentrations in the MLR supernatant were measured after 96 hours of culture, and IFN- γ , IL-3, and GM-CSF did not induce significant suppression of IL-2 production. TNF- α and TGF- β did suppress IL-2 production in the MLR but the addition of anti-TNF α and anti-TNF β antibodies does not affect the apparent suppressive activity of these factors; therefore, it does not appear that the suppression is in fact due to these factors.

The ability of the IC7 supernatants to suppress IL-2 production from T cells stimulated by mitogens or antibodies was also tested. In these assays, BALB/c splenocytes (5×10^5 /well) were cultured for 72 hours under conditions identical to those for the MLR in the presence of either ConA (2 μ g/ml), PHA (4 μ g/ml) or anti-CD3 monoclonal antibody (final 1/200 dilution of hybridoma cell culture supernatant) added to the splenocytes from the start of the assay. Again, the effect of a 1/5 final dilution of IC7 was tested on IL-2 production measured as described above.

The results are shown in Figures 2B-2D. As shown in Figure 2B, controls without ConA show no IL-2 production (open circles), but splenocytes stimulated with ConA (open squares) show a peak production of IL-

-36-

2 of 16 U/ml after 24 hours. Addition of IC7 does not appreciably affect this production (open triangles). Similar results were obtained using PHA as a stimulant (Figure 4C). As shown in Figure 4D, some enhancement
5 of IL-2 production induced by anti-CD3 stimulation is found; splenocytes stimulated with anti-CD3 produce about 2 U/ml IL-2 after about 6 hours and maintain this level until about 60 hours (open triangles). Addition of IC7 at a 1/5 dilution raises the IL-2
10 secretion to about 8 U/ml over the same time period.

Example 3

Purification and Characterization of NSF

A 2:l⁺ pool of IC7 was incubated with 7 mg/ml
15 silicic acid in PBS for 4 hours at 4°C under continuous stirring. The silicic acid was spun down and nonadsorbed material was collected and concentrated in a Centricell filtration unit with an
20 NW cut-off of 10 kd.

The resulting supernatant was dialyzed
against 20 mM Tris-HCl, pH 8.0, supplemented with 1 mM
PMSF, and run on a DEAE Sepharose column at 4°C using
the same buffer. The column was washed with 2 bed
volumes of starting buffer and the adsorbed material
25 was eluted at a flow rate of 0.35 ml/min with linear
gradient (0-1 M) of NaCl, 20 mM Tris-HCl, pH 8.
Fractions of 1 ml were collected and stored at 4°C
until tested in the MLR at a final dilution of 1/5.
MLR supernatants were collected after 72 hours and
30 screened for IL-2 content in the HT-2 assay using
thymidine incorporation.

The elution pattern is shown in Figure 3.
Measurement of protein content at 280 nm shows two
major peaks. However, the majority of the MLR
35 suppressor activity elutes between 0.2 and 0.4 M NaCl.
The material in fractions 106-112, as shown in Figure
3, was pooled, concentrated and dialyzed against PBS.

-37-

This active material blocked IL-2 production in MLR up to a 1/32 dilution.

Characterization of the purified factor (SF) showed that the activity was lost when SF was
5 acidified to pH 2 for 12 hours, boiled for 5 minutes, or protease-treated by incubating the dialyzates for 4 hours at 37°C with protease immobilized to agarose beads.

Further characterization of the nature of
10 the activity of SF was conducted on this purified factor. In one study, a 1/5 final dilution was added to the MLR at various time points, the supernatants were collected after 72 hours, and IL-2 production measured in the MTT assay. SF suppresses IL-2
15 production when added within the first 60 hours of the MLR, but when added later, at 66 hours, suppression is no longer shown. Further, in general, effectiveness of suppression diminished the later the SF was added to the reaction.

20 The effect of SF on APC was also determined by measuring IL-2 production by a T-cell hybridoma stimulated with antigen and Class II-matched APC. IE^{K+} 1G18-LA cell line, which is a cloned macrophage line from thymus, was incubated at day 0 with graded
25 concentrations of IFN- γ (100-0.5 U/ml) for 24 hours. The cells were washed and added to ovalbumin-specific and IE^K-restricted T-cell hybridoma line 3DO-18.3. The mixture was cultured for another 24 hours in the presence of ovalbumin, and at the end of the culture
30 period, supernatants were collected and screened for IL-2 content. The SF was added at 1/5 final dilution either to the culture of APC alone or APC plus hybridoma.

The results are shown in Figure 4 as a
35 function of IFN- γ concentration. As shown, APCs were incubated at day 0 with different IFN- γ concentrations, at day 1 the APC cultures were washed

-38-

and T cells added together with antigen, and at day 2 the supernatants were tested for IL-2 in the MTT assay. SF was able to suppress the production of IL-2 only when added at day 0 (open squares), not when added after the hybridoma had been included (open triangles), except at the lowest IFN- γ concentration. Controls are shown as open circles.

In an alternate system using IE^D-restricted sperm whale myoglobin-specific A.2.1DH1A T cell hybridomas with IE^{D+} A20B lymphoma cells in the presence of horse myoglobin or sperm whale myoglobin 110-121 peptide, similar but not identical results were obtained. In this case, suppression was shown whether or not the APCs were preincubated with SF.

15

Example 4

Effect of Cloned NS Cells on Thymocytes In Vitro

The cloned TCR $\alpha\beta$ ⁺, CD3⁺, CD4⁻, CD8⁻ NS cells represented by TLI-C7, rather than suppressing thymocyte proliferation in response to PHA, in fact stimulate this proliferation. The experiments demonstrating this capability of the cloned NS cells is described in detail by Van Vlasselaer, P., et al., Cell Immunol (1991) 136:1-15, the disclosure of which is incorporated herein by reference. However, these cloned cells suppress the MLR, as described previously.

Example 5

Correspondence of Fresh Mouse Bone Marrow Cells with Cloned Mouse Bone Marrow Cells

Fresh mouse bone marrow cells were subjected to Percoll density gradient separation. Low density cells were separated by flow cytometry, and a DNS population was obtained. The latter cells were shown to suppress the MLR by about 70% when 10⁵ cells were

-39-

added. Thus, both fresh and cloned DNS cells suppress the MLR.

Example 6

5 Preparation of Fresh Human Bone Marrow Suppressor Cells Enriched for Stem Cells

Bone marrow was obtained from normal adult donors for allogeneic bone marrow transplantation after informed consent had been given according to
10 guidelines established by the Stanford Committee for Human Subjects. Human bone marrow cells were either aspirated or taken from cores of bone marrow removed from the iliac crest. Single cell suspensions were separated using Ficoll-Hypaque gradients (Lymphoprep;
15 Nycomed AS, Oslo, Norway). These gradients were subsequently referred to as Ficoll gradients. The mononuclear fraction from this gradient is recovered. The recovered cells were depleted of monocytes by incubation twice on plastic petri dishes for 45
20 minutes at 37°C. Medium for incubation consisted of RPMI-1640 (Applied Scientific, San Francisco, CA), 10% fetal calf serum (HyClone, Logan, UT), 2 mM L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin and 50 µM 2-mercaptoethanol (ME). (Bone marrow cells
25 obtained from the Ficoll gradients were further depleted of myeloid and erythroid cells in some experiments in order to enrich for lymphocytes.) Ficoll-purified buoyant mononuclear cells were washed and incubated with phycoerythrin-conjugated mouse
30 monoclonal antibodies directed against human CD33 (Leu-M9; clone P67.6) (Becton-Dickinson, Mountain View, CA) and with mouse monoclonal antibodies to human glycophorin A (gift of J. Griffin, Dana Farber Cancer Center, Boston, MA) at 4°C for 30 minutes.
35 These steps were omitted in later experiments, as they were included in the initial determinations only to simplify the assay procedures on the separated cells.

-40-

To remove excess antibody, the incubation mixture was layered on a 1 ml cushion of calf serum and centrifuged at 250 xg for 10 minutes. The pellet was resuspended in phosphate-buffered saline (PBS) containing sheep antimouse antibody coupled to magnetic particles (Dynal, Inc., Great Neck, NY) and incubated as before. Cells were put on a magnetic particle concentrator (Dynal, Inc.) for 5 minutes. Nonbound cells were removed and washed twice. In some cases, mouse monoclonal antibodies directed against CD11b (Mo-1) (gift of J. Griffin) and against glycophorin A were used to remove myeloid and erythroid cells by "panning," as has been described by Greenberg, P.L., et al., Blood (1985) 65:190-197.

Percoll gradients were prepared using 2.5% or 5% steps ranging from either 40-50% Percoll or 45-55% Percoll (Pharmacia LKB Biotechnology, Uppsala, Sweden). The stock Percoll was prepared according to the manufacturers instructions except that when the stock was prepared, 12 parts Percoll to 1 part 10X physiological saline was used (as opposed to 9 parts Percoll:1 part 10X physiological saline). The stock solution prepared in this manner has an osmolality in the range of human blood of about 280-290 mOsm. The dilution of stock solution to the desired percentage Percoll gradients using RPMI then created the gradients for separation; these gradients were also, therefore, maintained at physiological osmolality. Before use, gradients were checked for pH, osmolality and exact density by refractometry (C. Zeiss refractometer).

The Ficoll purified, plastic nonadherent or lymphocyte-enriched marrow cells were mixed with the lowest density Percoll, placed on top of the discontinuous Percoll gradient, and centrifuged (550 xg) for 30 minutes at 20°C. Cells at each interface

-41-

were collected and washed before testing in the MLR or in the hematopoietic progenitor assays.

The results of one determination using 5% steps ranging from 45-55% Percoll are shown in Table

5 IA.

10

15

20

25

30

35

-42-

Table IA
Yield and Subsets of Marrow Cells After Fractionation

Marrow Cell Population	Percentage Yield ^a	Percentage of Cells Expressing Surface Marker	CD3 ⁺	CD4 ⁺	CD8 ⁺	CD16 ^{±b}
Unfractionated	100					
Ficoll Hypaque	52±11	17±10	9±3	9±3	ND ^c	
Plastic:						
Nonadherent	34±7	20±14	10±6	10±2	17	
Percoll Fractions:						
FR.1 (<45%)	0.9±0.7	6±5	2±1	2±1	18	
FR.2 (45-50%)	4±4	11±10	5±3	5±2	21	
FR.3 (50-55%)	7±4	20±14	10±5	8±4	2	
FR.4 (>55%)	8±6	33±24	15±6	15±6	4	

^a Mean percent yield ± SEM as compared to the number of unfractionated marrow cells in four experiments.

^b Average percentage of CD16⁺ cells in two experiments which were separate from those with other markers.

^c ND, not done.

-43-

Low density Percoll fractions 1 (<45% Percoll) and 2 (45-50% Percoll) yielded a mean of 0.9% and 4% of the original bone marrow samples, respectively (Table IA). This represents 3% and 11% of the plastic nonadherent cells. High density Percoll fractions 3 (50-55% Percoll) and 4 (>55%) yielded means of 7% and 8% of the original samples, respectively. This represents 20% and 24% of the nonadherent cells. The total yield of all fractions was 58% of the nonadherent cells. CD3 positive cells (T cells) were decreased in low density fractions (mean 6% in FR.1) as compared to bone marrow separated by Ficoll (Mean 17%). In contrast, CD3-positive cells were increased in high density fractions (33% in FR.4, Table I). Similarly, CD4 and CD8-positive cells were reduced in the low density fraction (both 2% in FR.1) as compared to bone marrow separated by Ficoll (both 9%), and to high density Percoll fractions (both 15% in FR.4). In contrast, CD16-positive cells (NK cell marker) were enriched in low density fractions (21% in FR.2) as compared to high density fractions (4% in FR.4).

In an additional experiment, plastic-nonadherent bone marrow cells were depleted of CD33⁺ and glycoporphin A⁺ (myeloid cells) by magnetic adherence. The depleted cells were purified further by Percoll density gradient fractionation, and compared to PBL prepared from the same donor. Cells were strained for TCR $\alpha\beta$ and counterstained for CD4 and CD8 markers.

Table IB shows the result of a Percoll fractionation using 5% steps ranging from 45-55% Percoll prepared as above.

-44-

Table IB
Percentages of CD4⁺ or CD8⁺ αβ⁺ and CD4⁺ CD⁺ αβ⁺
Cells in Fractionated Bone Marrow and PBL

Fraction	Percentage of Cells Expressing Surface Marker ^a CD4 ⁺ αβ ⁺ and CD8 ⁺ αβ ⁺	CD4 ⁺ CD ⁺ αβ ⁺	Ratio ^b
Ficoll Gradient and "Panning"	24	0.54	47
Percoll Gradient			
FR.1	12	0.8	15
FR.2	17	0.6	28
FR.3	34	1.2	28
FR.4	19	0.4	47
PBL	65	1.0	65

^a Percentage of cells staining positively for given surface marker in one of two similar experiments in which T cells in bone marrow were enriched by depletion of CD33⁺ and glycophorin A⁺ cells using magnetic beads. The same thresholds were used in all experiments.

^b The ratio of CD4⁺ αβ or CD8⁺ αβ⁺:CD4⁺ 8⁺ αβ⁺ cells was determined.

-45-

An average of 65% of PBL were CD4⁺ αβ⁺ and CD8⁺ αβ⁺ cells, and CD4⁻ and CD8⁻ αβ⁺ represented 1.0%. The average ratio of CD4⁺ or CD8⁺ αβ⁺:CD4⁻ CD8⁻ αβ⁺ was approximately 65:1. In contrast the ratio of CD4⁺ or CD8⁺ αβ⁺:CD4⁻ CD8⁻ αβ⁺ cells in the low density bone marrow fraction 1 was 15:1, and rose to 28:1 and 47.1 in the high density fractions 3 and 4, respectively. The change in ratio is mainly due to a depletion of CD4⁺ and CD8⁺ cells in the low density fractions without a depletion of CD4⁻ CD8⁻ αβ⁺ cells.

In an additional experiment, conducted as described above, but substituting 2.5% steps in the Percoll gradient and a 40-50% Percoll range, cells were tested for the presence of CD34 markers as well as the background concentration of CD3⁺, CD4⁺, CD8⁺ marked cells. The results in Table II show enrichment for the CD34⁺ marked cells in the lower percentage Percoll fractions with some variation between patients. These separations were conducted on cells prepared by a modification of the foregoing procedure wherein bone marrow cells were first treated with heta starch solution to remove red blood cells followed by a Ficoll-Hypaque gradient for removal of polymorphonuclear cells. Generally, substantial numbers of cells were recovered although the percentage of total cells after the first two steps ranged from about 20% to about 75% of the total bone marrow cells.

30

35

-46-

Table II
% of CD34⁺ Cells
Patient #

	<u>Fraction</u>	1	2	3 [†]	4 [†]	5 [†]	6 [†]	7 [†]
5	Bone marrow	0.3	4.9	1.3	0.5	ND	ND	1.2
	Heta Starch	0.7	1.9	0.7	0.1	ND	ND	0
	Ficoll Hypaque	1.1	2.0	0.2	2.0	1.2	ND	3.6
10	Percoll:							
	I (40-42.5%)	4.5	15.3	5.2	6.0	9.9	25.6	4.3
	II (42.5-45%)	13.6	19.6	25.8	12.7	6.3	15.6	9.1
15	III (45-47.5%)	10.1	7.3	15.2	6.4*	1.2	7.1	15.0
	IV (4.75-50%)	3.8	1.2	0	4.3	1.0	1.5	2.0
	V (>50%)	0.2	0.1	0	2.5	0.1	0.1	1.1
20	† The values given are corrected for background. * Not corrected.							

As shown in Table II, Percoll gradients succeed in separating enriched populations of CD34⁺ cells. These cells can be stored until needed for use to aid in graftment in autologous transplants or for stem cell replacements in patients undergoing chemotherapy. While there is variability among patients as to the fraction containing the enriched population, in general, enrichment occurs in the lowest density fractions. These fractions (I+II+III) constitute 25% of the original cell population.

As set forth above, the fractions should be assayed for the CD34 marker to verify which fractions should be retained. In the case of allogeneic transplants, in addition, the T-cell component should be assessed by monitoring CD3, CD4 and CD8.

The foregoing separation method was also applied to white blood cells that had been obtained

-47-

using a commercial leukophoresis apparatus to process the blood of a cancer patient. The white blood cells obtained using the standard procedure were subjected to Ficoll-Hypaque gradient separation to recover only mononuclear cells and then subjected to Percoll gradient separation using 2.5% steps between 40-50% Percoll, as described above. About 15 billion cells, about 1% of which contained CD34 markers, were subjected to the Percoll gradient separation, and the low density fractions contained about 1.2 billion cells, about 10% of which were CD34⁺. Thus, about 60-70% of the CD34⁺ cells in the original population were recovered.

15

Example 7Results of MLR Using FractionatedBone Marrow Cells as Responders

To conduct the MLR, responder and stimulator cells were cultured at a concentration of 1×10^5 cells each in a final volume of 0.2 ml per well in flat-bottom microculture plates (Costar, Cambridge, MA). Cultures were incubated for 120 hours at 37°C with 5% CO₂. Stimulator cells were irradiated with 3000 cGy from a ¹³⁷Cs source (Mark I model 125 irradiator, J.L. Shepherd and Associates, Glendale, CA).

DNA synthesis was assayed by the addition of 1 μCi of tritiated thymidine (³H-TCR, specific activity 6.7 Ci/mM, New England Nuclear Corp., Boston, MA) to each well during the final 18 hours of incubation period. Radioactivity was measured in a liquid scintillation counter (Beckman Instruments, Inc., Fullerton, CA). Experiments were performed in triplicate, and values are expressed as means. Standard errors were less than 10% of the mean in almost all cases.

Cells from various Percoll fractions from Example 6 were added to irradiated allogeneic

-48-

stimulator cells and tested as responder cells in the MLR. Low density Percoll fractions were poor responders, and ^3H -TCR incorporation was similar to background. High density fractions gave vigorous responses which were about 3.5 times greater than that of the former. The response of high density marrow cells were similar to that of PBL (see Figure 5).

Unfractionated and low density fractions of rodent bone marrow cells have been reported to suppress the MLR (Weigenberg, M., et al., J Immunol (1983) 132:971-978; Noya, S.J., et al., J Leuk Biol (1988) 43:279-287). In the current study, the suppressive activity of unfractionated and fractionated human bone marrow cells irradiated in vitro (3000 cGy) was tested. A typical example of the effect of various Percoll fractions added to the MLR is shown in Figure 6. ^3H -TdR incorporation in the MLR without the addition of cocultured cells is set as 0% suppression. In contrast to the results in mice, unfractionated irradiated human bone marrow enhanced ^3H -TdR incorporation by about 10% when added to the MLR. The lowest density marrow cells (FR. 1) suppressed the MLR by about 50%. High density cells of FR.3 has little effect, and high density marrow cells of FR.4 enhanced ^3TdR incorporation by about 40%.

Example 8

Ability of Cell Fractions to Suppress the MLR

In the conduct of the assay, irradiated (3000 cGy) cells to be tested were added at a variety of concentrations to 96-well, flat-bottomed microtiter plates containing 1×10^5 responder and 1×10^5 irradiated (3000 cGy) stimulator cells/well in a final volume of 200 μl . Controls included addition of irradiated responder cells instead of putative suppressor cells, or no addition of cells. Cultures were incubated at 37°C in 5% CO_2 . After 120 hours,

-49-

plates were pulsed with 1 μ Ci/well 3 H-TdR as described above. All experiments were performed in triplicate. Percentage suppression was calculated as $[1 - (\text{cpm with cocultured cells}) / \text{cpm without cocultured cells}] \times 100$.

5 Purified CD16⁺ (bright) cells were obtained by flow cytometry from low density marrow cells (FR1 and FR2) of Example 6, and then added in graded doses to the MLR using autologous responder PBL and allogeneic stimulator PBL. In control experiments, purified CD3⁺
10 (bright) cells from the low density fractions, as well as unsorted low density cells were added to the MLR. Neither the sorted CD16⁺ nor the CD3⁺ cells inhibited 3 H-TdR over the dose range tested. However, the unsorted low density cells were able to suppress the
15 response, and about 40% suppression was observed with 1×10^5 cocultured cells.

Since CD4⁻ CD8⁻ $\alpha\beta$ ⁺ cells from the low density fractions of normal mouse bone marrow are able to suppress the MLR-purified populations of sorted human
20 CD4⁻ CD8⁻ $\alpha\beta$ ⁺ cells were tested for their suppressive activity in the MLR. In order to obtain sufficient numbers of these cells, marrow cells were separated on a Ficoll gradient, and then "panned" to remove myeloid cells with anti-MO-1 (anti-CD11b) and anti-glycophorin
25 A monoclonal antibodies. The nonadherent cells were stained with fluorescein-conjugated anti- $\alpha\beta$ TCR and phycoerythrin-conjugated anti-CD4 and anti-CD8 antibodies. Two-color analysis of these cells was compared to similarly stained PBL from the same donor.

30 A discrete population of CD4⁻ CD8⁻ $\alpha\beta$ ⁺ cells was observed in bone marrow cells of some donors but not with PBL. The CD4⁻ CD8⁻ $\alpha\beta$ ⁺ and CD4⁻ CD8⁻ $\alpha\beta$ ⁻ populations of marrow cells were purified by flow cytometry, and reanalyzed for their surface marker
35 patterns. The intensity of staining for the CD4 and CD8 markers was dull in both populations and overlapped. However, the pattern for TCR $\alpha\beta$ staining

-50-

showed a clear separation of bright and cull cells such that less than 5% contamination was noted. Graded numbers of CD4⁺, CD8⁺, TCR $\alpha\beta$ ⁺ and DNS cells were added to the MLR. Although both populations

5 suppressed the ³H-TdR incorporation by about 40%, the DNS cells were approximately five times more efficient than the DNS population. Unsorted marrow cells separated on Ficoll and "panned" as above failed to suppress the MLR over the dose range tested. The lack

10 of suppression by the unsorted cells may be related to the presence of CD4⁺ or CD8⁺ cells which may enhance the MLR, and to the low percentage of DNS cells.

Example 9

Enrichment of Fractionated Bone Marrow Cells for Suppressor Activity

The fractions of bone marrow prepared as in Example 8 which are enriched in DNS are further enriched in this phenotype population by culturing in

20 the presence of suitable growth factors. The appropriate growth factors can readily be assessed by routine supplementation of the media and testing the resulting populations for their ability to suppress the MLR.

25

Example 10

Suppression of Spleen Enlargement by Cloned NS Cells

When foreign immunocompetent cells are

30 supplied in sufficiently small amounts relative to the state of immunosuppression of the host, the foreign (donor) cells are generally not lethal to the host, but the host displays a measurable response in the form of spleen enlargement. An assay for

35 graft-versus-host disease based on this observation was disclosed by Simonsen, M., Prog Allergy (1962) 6:349-467. This assay for sublethal graft-versus-host

-51-

disease was used to determine the effect of TLI-2.4C and 4BA4 cell lines on this response.

To determine the proper dosage level for the donor cells, 0.5, 1, 5, or 10×10^6 adult C57BL/Ka spleen cells were injected into the F1 cross BALB/c x C57BL/Ka neonatal hosts. The adult (8-12 weeks old) dissociated spleen cells were prepared in tissue culture medium RPMI-1640 (Gibco, Grand Island, NY) and injected intraperitoneally in 0.1 ml into the F1 cross on day 4-7 after birth. Eight days later recipient spleens were removed and assayed. Injection of 5×10^6 cells was shown to give an easily measurable response of the order of a 2.4-fold (average) increase in spleen size, and was on the dose responsive portion of the curve obtained, shown in Figure 2.

Spleen indices were calculated and represent the ratio of the weight of the spleens of injected mice to the weights of uninjected litter mate controls. Indices greater than 1.0 are indication of graft-versus-host disease.

Table III shows the results obtained when the subject neonates were injected intraperitoneally with 5×10^6 C57BL/Ka spleen cells 4-7 days after birth with and without NS cells or control HT-2 cells and the spleen indices measured 8 days later. As expected, controls injected with 5×10^6 F1 hybrid spleen cells showed no spleen enlargement.

30

35

-52-

Table IIISpleen Index
(Mean)

5	No addition	2.6
	+15x10 ⁶ TLI-2.4C	1.2
	No addition	2.7
	+15x10 ⁶ 4BA4	1.8
10	No addition	2.5
	+15x10 ⁶ HT-2	2.3
	No addition	2.6
	+5x10 ⁶ TLI-2.4C	1.6
	No addition	2.5
	+5x10 ⁶ HT-2	2.3

The results are clear that co-injection of either TLI-2.4C or 4BA4 cells at 15 x 10⁶ cells is effective in suppressing graft-versus-host disease as measured by the spleen enlargement caused by the foreign cells. Reducing the NS cells injected to 5 x 10⁶ reduced the amount of suppression but did not destroy it. A control T-cell line (HT-2) does not suppress.

25

Example 11Suppression of Lethal Graft-Versus-Host Disease
by Cloned NS Cells

When similar administrations of foreign tissues are made to irradiated weanling hosts, the response is not limited to spleen enlargement, and the injections are generally fatal. Previous studies have shown that sublethally irradiated adult BALB/c mice injected IV with C57BL/Ka spleen cells are killed within two weeks. This is in part due to the high concentration of T cells in the spleen.

BALB/c weanlings were given 400 rad whole body irradiation 6-12 hours before administration of 5

-53-

x 10⁶ C57BL/Ka spleen cells in 0.5 ml RPMI1640, either alone or in combination with the NS cells. Under these circumstances, BALB/c 21 day old weanlings injected intraperitoneally with C57BL/Ka spleen cells were killed (85% die by 30 days). As would be expected, C57BL/Ka weanlings similarly treated survive. However, for BALB/c mice receiving 15 x 10⁶ cloned NS cells (TLI-2.4C) co-injected with the C57BL/Ka spleen cells, only 5% of the hosts died after 30 days. Co-injections of 15 x 10⁶ 4BA4 cells are only slightly less effective. Co-injection with HT-2 cells gave results similar to those of the controls. These results are summarized in Figure 7, where the numbers in parentheses show the number of mice in each group. The survival rates at 100 days were the same as those shown for 40 days in the Figure. Those few mice receiving co-injected HT-2 cells which did survive were runt.

It is clear from the foregoing results that the cloned NS cells are capable of suppressing the acute graft-versus-host disease mounted against immunocompromised hosts. (It should be noted that intraperitoneal injection of the spleen cells and of the NS cells was essential; similar experiments conducted intravenously were not successful, possibly due to failure of NS cells to migrate to the host spleen and interact with the donor cells.)

The conditions of the in vivo treatment performed above, however, did not result in the NS-cells conferring chimeric characteristics on the host. To demonstrate this, peripheral blood mononuclear (PMN) cells were assessed for the presence of C57BL/Ka donor cells. PMN were isolated from surviving hosts after 30 days of test period, and incubated with anti-C57BL/Ka antiserum with complement in a microcytotoxicity test performed as described by Slavin, S., et al., J Exp Med (1977) 146:34-48. Where

-54-

C57BL/Ka characteristics present in any PMN cells, cell death would have resulted; however, none was observed. Also, these hosts were not capable of accepting C57BL/Ka skin grafts within 2 wk after the
5 initial injection.

Example 12

Cloned NS Cells Are Permissive to Establishment of Chimeric Nature and Immunotolerance

10 While the NS cells were shown to protect subjects against the acute response produced against injection of allogeneic spleen cells, these spleen injections failed to confer the desired immunotolerance and chimerism on the host. This
15 failure may be due to the nature of the injected tissue and thus its failure to repopulate the host bone marrow and spleen with C57BL/Ka hematopoietic stem cells. Spleen cells contain a high population of T-lymphocytes, thought to be responsible for the acute
20 graft-versus-host disease, but a relatively low population of stem cells, which are relatively undifferentiated and are thought to be responsible for, or at least essential to, production of immunotolerance.

25 Accordingly, procedures similar to those above were conducted using bone marrow rather than spleen cells as the source of foreign tissue. Adult BALB/c mice were given lethal whole body irradiation (700 rad) one day before intraperitoneal injection of
30 50×10^6 C57BL/Ka bone marrow cells; with or without 15×10^6 TLI-2.4C cells. 12 of 14 mice survived 30 days later without evidence of graft-versus-host disease when the NS cells were co-injected. Among controls given no NS cells, 8 of 10 survived.

35 PMN from all surviving animals were tested by the microcytotoxicity assay as above and found to be chimeras as shown by 95% killing of PMN cells.

-55-

Further, they were able to accept C57BL/Ka, but not C3H, skin grafts after 40 days.

The spleen cells of the chimeras were further tested for their ability to induce
5 graft-versus-host disease in fresh BALB/c mice recipients. Normal C57BL/Ka donor cells, when injected at 10×10^6 spleen cells intraperitoneally in 0.5 ml RPMI-1640 medium into either BALB/c or C3H recipients result in the death of all mice injected
10 within 14 days. As would be expected, control mice having no cells injected survived. Spleen cells of the chimeras, injected similarly into BALB/c or C3H mice, induced graft-versus-host disease only in the C3H recipients; the BALB/c recipients survived
15 injection of the chimeric spleens whether derived from chimeric donors given a C57BL/Ka bone marrow injection alone or in combination with NS cells. The immunotolerance conferred on the chimeric donors was specific to BALB/c recipients.

20

Example 13

Properties of Fractions of Spleen and Bone Marrow Cells

Spleen cells were removed aseptically from
25 C57BL/Ka(H-2⁶) mice, and single cell suspensions were prepared by gently pressing the spleen fragments through a nylon fiber mesh into cold RPMI-1640 medium. Bone marrow cells were prepared by flushing the femora and tibiae of C57BL/Ka(H-2⁶) mice (4-10 weeks old) with
30 cold RPMI-1640 medium using a 25-gauge needle. Bone marrow plugs were then gently resuspended. The cells were washed twice and counted in 2% acetic acid before use, and viability was determined by trypan blue dye exclusion.

35 Percoll (Pharmacia, Uppsala, Sweden), composed of colloidal silica coated with polyvinyl pyrrolidone, was first made isotonic for use with

-56-

living lymphocytes. Calcium and magnesium-free 10 x DPBS was added to the stock solution of Percoll in a ratio of one part (v/v) DPBS to nine parts (v/v) Percoll (starting density 1.130 g/ml), and it was
5 adjusted to pH 7.2. For subsequent use, this working stock solution was progressively diluted in RPMI-1640 medium to obtain solutions containing 40, 50, 55, 60 and 70 percent of Percoll. Corresponding densities (g/ml) were 1.050, 1.060, 1.068, 1.075, 1.090,
10 respectively. Two to three ml volumes of each of the Percoll solutions, starting with the 70% concentration and continuing with the decreasing concentrations, were layered in 15 ml clear polystyrene tubes using a 5 ml pipette. A variable number of spleen or bone
15 marrow cells (not exceeding 100×10^6 cells) were suspended in 300 μ l of RPMI-1640 medium to layer over the Percoll gradients. The gradient was centrifuged at 2000 rpm (520 g) for 30 minutes at room temperature and the cells at each density interface were aspirated
20 with a Pasteur pipette and washed with RPMI-1640. The results of gradient fractionation are shown in Table IV.

25

30

35

-57-

Table IV
 Percoll Fractionation of Spleen and Bone Marrow Cells:
 Percent Yield and Percent of Thy-1⁺ Cells^f in Each Fraction

Percent Percoll (v/v)	Density of Percoll (g/ml)	Percent Yield of Spleen Fraction (Range) ^a	% Thy-1.2 Pos- itive Cells In Spleen Fraction (Range) ^b	Percent Yield of Bone Marrow Fraction (Range) ^a	% Thy-1.2 Pos- itive Cells In Bone Marrow Fraction (Range) ^b
40	1.050	1-2	17-25	1-2	12-15
50	1.060	2-4	17-25	1-3	15-16
55	1.068	5-8	25-30	29-45	13-17
60	1.075	17-29	46-60	15-23	7-12
70	1.090	5-7	60-75	1-4	ND

^a Percent yield determined by number of cells applied to gradient as compared to the number obtained from each fraction. Range was determined from two to six independent experiments.

^b Range is shown for three independent experiments.

-58-

The fractions were also stained for the presence of CD4, CD8 and TCR $\alpha\beta$ surface markers using monoclonal antibodies. Cells that are $\alpha\beta$ TCR in the unfractionated spleen stain brightly for all three surface markers (41% of total cells). Unfractionated bone marrow cells contained less than 1% of cells with a similar bright staining pattern for all three T-cell surface markers. The majority of bone marrow T cells which stained positively for the $\alpha\beta$ TCR were CD4⁺ and CD8⁺.

Analysis of bone marrow fractions showed little change in the staining pattern of T cells, since the $\alpha\beta$ TCR⁺ CD4⁺ CD8⁺ cells were predominant in both high and low density fractions. Spleen cell fractions contained brightly staining CD4⁺, CD8⁺ and $\alpha\beta$ TCR⁺ cells as most abundant (38%) in the high density fraction (FR60) and depleted (12%) in the low density fraction (FR50). A substantial percentage (13%) of $\alpha\beta$ TCR⁺ CD4⁺ CD8⁺ cells was in the low density fraction (FR50). The predominant T-cell subset in the bone marrow can also be found in the spleen, but the predominant spleen subset was undetectable in the marrow.

25

Example 14

Use of Enriched or Sorted Fresh NS Cells to Inhibit GVHD and Promote Chimerism

In the GVHD assay, three to four week old BALB/c mice received a single dose of sublethal total body irradiation (TBI) (400 rad), 6 to 18 hours prior to the i.v. infusion of cells. To induce GVHD, a single inoculum of C57BL/Ka cells was given. For suppression of GVHD, BALB/c mice were given a combination of 2.5×10^6 CF57BL/Ka spleen cells, and various doses of fractionated adult C57BL/Ka bone marrow and spleen cells obtained from discontinuous Percoll gradients. Control groups received only 400

-59-

rads sublethal irradiation alone, or 400 rads sublethal irradiation and 2.5×10^6 syngeneic (BALB/c) unfractionated spleen cells. Mortality in all groups was recorded daily.

5 One hundred days after cell transfer in the GVHD assays, surviving mice were assayed for the presence of donor-type lymphocytes in the peripheral blood, identified by a complement-dependent microcytotoxicity assay. Recipients were bled from
10 the retro-orbital sinus, and blood samples were heparinized. Ficoll-hypaque gradient purified peripheral blood lymphocytes were incubated for 30 minutes at 37°C with BALB/c anti-C57BL antiserum (final dilution 1:10) prepared as described by Okada,
15 S., et al., Transplantation (1983) 36:417. After the incubation, Low-Tox-M rabbit complement (Accurate Chemicals and Scientific Co., Hicksville, NY) diluted 1:4 was added to the samples. The reaction mixture was again incubated at 37°C for 45 minutes. Cells
20 were harvested in medium containing trypan blue, and the viability of cells observed in a standard hemocytometer. The net cytotoxicity was calculated by comparing the number of viable cells present after treatment with antiserum with the number present after
25 treatment with normal BALB/c serum. Control cytotoxicity tests with normal C57BL/Ka mice gave values of >95%, and with normal BALB/c mice gave values of <5%.

 After induction of GVHD by unfractionated
30 C57BL spleen cells in sublethally (400 rads) irradiated BALB/c hosts, none of the recipients given 2.5×10^6 cells survived more than 11 days. Approximately 50% given 1×10^6 cells survived more than 100 days, and 100% given 0.5×10^6 cells more than
35 100 days. Recipients given 2.5×10^6 or 5×10^6 unfractionated C57BL bone marrow cells, or no cells all survived more than 100 days.

-60-

The in vivo GVHD inductive capacity of the different spleen cell factions were measured by injecting (intravenously) 2.5×10^6 cells into sublethally irradiated BALB/c recipients. All animals given 2.5×10^6 spleen cells from FR40 or FR50 survived more than 100 days, and none showed obvious clinical signs of GVHD, such as ruffled fur, hunched back, facial swelling, diarrhea, hair loss or cachexia. All the BALB/c recipients injected with 2.5×10^6 spleen FR55 cells died by day 20, and none of the animals which received 2.5×10^6 FR60 cells survived more than 10 days. All the control animals injected with 2.5×10^6 unfractionated C57BL/Ka spleen cells died by 11 days, and the recipients given 400 rads sublethal irradiation alone survived 100 days.

None of the high or low density fractions induced lethal GVHD during the 100-day observation period.

C57BL/Ka bone marrow fractions were tested for their capacity to suppress GVHD induced by 2.5×10^6 unfractionated C57BL/Ka spleen cells. Coinjection of 2.5×10^6 FR60 or FR50 + 55 bone marrow cells into sublethally irradiated BALB/c recipients allowed more than 60 percent of the animals to survive more than 100 days. The greatest protection was observed with the lower density fraction (more than 80% survival). A variable proportion of the recipients that survived more than 100 days showed signs of mild chronic GVHD, including ruffled fur, hair loss, and weight loss depending on the individual experiment. Approximately 20 percent of the recipients coinjected with 2.5×10^6 unfractionated bone marrow cells survived more than 100 days. All BALB/c recipients which received 2.5×10^6 C57BL/Ka unfractionated spleen cells alone died by day 21, but all animals given irradiation alone or irradiation plus 2.5×10^6 syngeneic (BALB/c)

-61-

unfractionated spleen cells survived more than 100 days.

The C57BL/Ka spleen cells fractionated on Percoll gradients (2.5×10^6 cells from each fraction) were coinjected with 2.5×10^6 unfractionated C57BL spleen cells into sublethally irradiated BALB/c recipients. Both FR40 and FR50 allowed more than 80% of recipients to survive for more than 100 days. On the other hand, none of the recipients survived more than 20 days when 2.5×10^6 FR55 or FR60 cells were coinjected with the unfractionated spleen cells. All control animals that received 2.5×10^6 unfractionated spleen cells alone died by day 20, but all recipients given radiation alone or radiation and 2.5×10^6 BALB/c unfractionated spleen cells survived more than 100 days.

Graded numbers of FR50 spleen cells were coinjected with a constant number (2.5×10^6) of unfractionated C57BL spleen cells into sublethally irradiated BALB/c recipients. Coinjection of 2.5×10^6 FR50 cells allowed more than 80 percent of the BALB/c recipients to survive for more than 100 days. Coinjection of 1×10^6 and 0.5×10^6 cells resulted in 70 and 50 percent survival for 100 days, respectively. However, 90 percent of the animals coinjected with 0.1×10^6 cells died of GVHD within 20 days. All the animals which received 2.5×10^6 unfractionated spleen cells alone died within 21 days, but all the control animals given sublethal irradiation alone survived more than 100 days.

Several groups of BALB/c recipients were tested for chimerism at 100 days using BALB/c anti-C57BL/Ka polyclonal antibody and complement. Recipients of unfractionated C57BL/Ka bone marrow alone or C57BL/Ka bone marrow fractions (Group 1) alone, or spleen fractions (Group 5) alone were not chimeric, but the groups which received unfractionated

-62-

C57BL/Ka spleen cells plus low density bone marrow (Group 2; FR50) or spleen (Group 3; FR40, Group 4; FR50) cells were chimeric with a mean of 73, 74 and 91 percent donor-type cells, respectively. In addition, fresh FACS sorted cells shown to have the CD4⁺, CD8⁻ $\alpha\beta$ ⁺ phenotype are demonstrated to inhibit GVHD, and promote chimerism.

Skin grafts applied to recipients shown to be chimeric with respect to the donor skin were able to tolerate the grafts indefinitely; however, nonchimeric recipients rejected such grafts, and grafts derived from donor types not related to the chimera were rejected within three weeks.

Example 15

Characteristics of

Murine Bone Marrow T Cells with Suppressor Activity

A publication by Palathumpat, V., et al., J Immunol (1992 148:373-380, the contents of which are incorporated herein by reference, characterizes the suppressor cells in murine bone marrow. The study showed that the predominant T cell subset in the bone marrow of specific pathogen-free C57BL/Ka and BALB/c mice had the DNS surface phenotype. These DNS cells, when obtained by cell sorting, were successful in suppressing the mixed lymphocyte reaction. The percentage of typical T cells in the spleen was reduced in adult nude mice or normal neonatal mice, as compared to the normal adult; however, the percentage of cells with the DNS phenotype in the spleen and marrow was not.

The predominant subset of marrow T cells in pathogen-free mice differ with regard to surface marker phenotype, function, dependence on adult thymus, and deletion of certain self-reactive V β receptors when compared to typical cell T cells. The marrow T cells appeared to develop directly from

-63-

marrow precursors without rearranged β chains during a 48 hour in vitro culture.

Example 16

5 Effect of Subsets of T Cells in Adult Mouse
 Bone Marrow and Spleen with Respect to GVHD

 In an additional publication by Palathumpat, V., et al., in J Immunol (1992) 148:373-380, the disclosure of which is incorporated herein by
10 reference, fractionation of normal adult mouse spleen and bone marrow cells from C57BL/Ka mice was performed by discontinuous Percoll density gradients. Spleen cells in the fraction of 1.150-1.060 g/ml completely suppressed acute lethal GVHD when coinjected with
15 unfractionated C57BL/Ka spleen cells into sublethally irradiated (400 rad) BALB/c mice. As few as 5×10^7 of these low density cells suppress acute GVHD induced by 2.5×10^6 unfractionated allogeneic spleen cells.

 On the other hand, the high density fraction
20 of spleen cells, 1.075-1.090 g/ml induced acute GVHD in sublethally irradiated BALB/c recipients.

 Fractionation of C57BL/Ka bone marrow cells showed that none of the high or low density fractions or the unfractionated cells induced lethal GVHD.
25 Furthermore, fractions of all recovered densities protected BALB/c recipient mice from GVHD when coinjected with C57BL/Ka unfractionated spleen cells; unfractionated bone marrow cells were modestly protective. The low density bone marrow fraction
30 (1.050-1.068 g/ml) showed reproducible protection could be achieved at a 5:1 ratio of inducing to suppressing cells.

 The low density fractions of both bone marrow and spleen cells had marked depletion of TCR $\alpha\beta$,
35 CD4⁺ or CD8⁺ T cells in a predominant population of cells with a DNS phenotype. Purified populations of these DNA cells suppressed GVHD. Furthermore,

-64-

recipients given unfractionated C57BL/Ka spleen cells and protected with low density bone marrow or spleen cells were chimeras, and can accept allogeneic transplants.

5

Example 17

Purification of SF

The TLI-2.C7 clone was derived from the spleen of an adult BALB/c mouse given total lymphoid irradiation (TLI). Cells were expanded in IL-2 enriched medium without addition of exogenous antigen, cloned by limiting dilution, and expressed CD4⁻ CD8⁻ $\alpha\beta$ ⁺ cell surface marker phenotype. The cell line was maintained in RPMI-1640 supplemented with heat inactivated 10% FCS, 10 mM HEPES, 2 mM glutamine and 5x10⁻⁵ M 2-ME. For culture supernatants from concanavalin A stimulated rat spleen cells (CAS) (30% v/v) were added to the medium.

The TLI-2.C7 cells were grown to confluence in medium enriched with CAS in T-75 flasks. PMA (10 ng/ml) and A23187 (0.26 μ g/ml) were dissolved in RPMI 1640 supplemented with 10% heat inactivated FCS and added to the cells in a final volume of 20 ml/flask. After incubation for four hours, the cells were washed five times with PBS and overlaid with RPMI-1640 containing no additional proteins. The crude supernatants were collected 24 hours later and kept frozen at -40°C until use.

Two liter pools of supernatants were incubated with 7 mg/ml silicic acid in PBS for 4 hours at 4°C with continuous stirring. The silicic acid was then spun down and the nonadsorbed material was collected and concentrated in Centricon Filtration units (Polysciences, Inc., Warrington, PA) with a m.w. cutoff of 10 kDa; 0.1 mM PMSF was added to prevent degradation.

-65-

The nonadsorbed supernatant was dialyzed against 20 mM Tris-HCl (pH 8.0) buffer supplemented with 1 mM PMSF, and run on a DEAE-Sepharose column at 4°C using the same buffer. After a wash with 2 bed
5 volumes of starting buffer, the adsorbed material was eluted at a flow rate of 0.35 ml/min with a linear gradient (0-1.0 M) of NaCl, 20 mM Tris-HCl buffer (pH 8.0). Fractions of 2 ml were collected and stored at 4°C until use in the bioassay, or frozen at -70°C for
10 later study. The different fractions were added to the MLR at a final 1/5 dilution and the MLR supernatants screened for IL-2 after 72 hours in the HT-2 assay using (³H)-TdR incorporation. The elution portion is shown in Figure 9; fractions eluting at
15 0.2-0.4 NaCl showed activity; two protein peaks eluted, one corresponding to the activity.

The fractions containing activity were pooled, dialyzed against 5 mM Tris-HCl, 1 mM PMSF, pH 8.0 buffer, and applied to a lentil-lectin Sepharose
20 4B column equilibrated in the same buffer. After washing with 4 bed volumes of starting buffer, bound proteins were eluted with a linear gradient (0-0.3 M) of α -methyl-D-mannoside in the same buffer at a flow rate of 0.20 ml/min. Fractions of 2 ml were collected
25 and assayed as described above. The elution pattern is drawn in Figure 10. Only two fractions contained appreciable activity, as shown. Table V summarizes the purification steps.

30

35

-66-

Table V
Purification of NSF

Purification Step	Volumes (ml)	Total Protein (mg)	Total Suppressive (U)	Specific Activity (U/mg)	Purification (fold)	Recovery (%)
Supernatant	2,000	56.6	80,000	1,410	1	100
Silicic Acid	1,980	21.0	150,000	7,540	5	198
DEAE-Sepharose	16	0.160	10,240	64,000	45	13
Lentil-Lectin	6	0.019	7,440	387,500	275	91a

-67-

Overall, a 275-fold purification and 9% yield were achieved.

Aliquots of the pooled active fractions containing 500 ng protein eluted from the lentil-
5 lectin column were separated by SDS-polyacrylamide (12.5%) gel electrophoresis under non-reducing conditions. The gels were sliced, aliquots were eluted from each fragment, and the eluates were assayed for suppressive activity; additional gels were
10 run in parallel under reducing and nonreducing conditions with 50 ng of protein to identify bands by silver stain. Two bands were visualized at approximately 20 kd (dense band) and 40 kd (light band) in three separate experiments. Assays of the
15 suppressive activity showed activity associated with the 20 kd region, some activity was in a higher molecular weight region not associated with a distinct silver-stain band. Approximately 4 μ g of the lentil-lectin pooled sample was subjected to N-
20 terminal Edman degradation using an automated peptide sequencer. A major and a minor amino acid sequence was observed consistent with SDS-PAGE which showed a major 20 kd band, and a minor 40 Kd band. The major amino acid sequence was X-Glu-Asn-Val-Gly-Leu-Asn-Glu-
25 Val-Val-(Ala/Phe)-Leu-(Lys/Leu)-Tyr-Gln-Val. The amino acid in the first position could not be clearly distinguished.

Example 18

30 Preparation of Antibodies

Antibodies were prepared by immunization with the peptides Leu-Asn-Glu-Val-Val-Ala-Leu-(Lys/Leu)-Tyr-Gln-Val which were conjugated to core polymer matrix (Ala-Lys₇-Gly₃).

35 Male New Zealand rabbits were immunized with subcutaneous injections of one of the two synthetic peptides; first with 100 μ g of the synthetic peptide

-68-

conjugates mixed with an equal volume of Freund's complete adjuvant. Ten days later, the animals were bled, and the injection was repeated with the antigen mixed in an equal volume of Freund's incomplete
5 adjuvant. Ten days later, the animals were bled, and after a third cycle, the rabbits were sacrificed and blood was allowed to clot and spun at 3,000 rpm for 20 min. The serum was loaded on an Affi-Gel Protein A column (Bio-Rad Inc.), previously equilibrated with
10 PBS. The column was washed with 5 volumes of PBS, and the IgG antibodies were eluted with an acid wash consisting of 0.3 M glycine-HCl pH 2.8.

IgG serum antibodies used below were obtained 10 days after the first immunization. A
15 single band was detected by Western blot using post-bleed but not with pre-bleed antibodies corresponding to the 20 kd band in both the DEAE and lentil-lectin eluates separated by SDS-PAGE. Rabbit serum IgG antibodies obtained after, but not before,
20 immunization with peptide bound on Western blot to lentil lectin purified material described above which was further purified with HPLC to obtain a 20 kd fraction.

Pre-bleed and post-immunization IgG serum
25 antibodies were conjugated to Affi-Gel 10 and incubated overnight with crude TLI-2C7 supernatants that showed high levels of suppressive activity. While untreated crude supernatant completely inhibited IL-2 secretion in the MLR up to a dilution of 1:2048,
30 and showed 50% inhibition at a dilution of 1:8192, after incubation with coupled antibodies, no suppressive activity was observed even at 1:32 dilution.

-69-

Claims

1. A mammalian cell line including the progeny thereof wherein said cell line is a double
5 negative suppressor (DNS) cell line characterized by a surface marker pattern which is IL-2R⁺, Ig⁻, CD4⁻, CD8⁻, CD3⁺, MAC-1⁻, TCRαβ⁺, or

which cell line is a null cell line characterized by a surface marker pattern which is
10 IL-2R⁺, Ig⁻, CD4⁻, CD8⁻, CD3⁻, MAC-1⁻, TCRαβ⁻, and wherein said each of said cell lines inhibits the mixed lymphocyte reaction (MLR) *in vitro*, but does not kill corresponding target cells.

15 2. A cell population derived from a blood cell source:

wherein said cell population is enriched in suppressor cells of the double negative suppressor (DNS) and/or null phenotype as compared to
20 unfractionated cell populations from said blood cell source, or

contains an effective amount of suppressor cells of the DNS and/or null phenotype and said population is free of sufficient number of
25 counteracting cell phenotypes so as to retain suppressive activity of the cell population.

3. A population of cells consisting essentially of about 5% or less of total human bone
30 marrow cells,

wherein said 5% or less represents the low density fraction from gradient separation of cells from human bone marrow, or

wherein said 5% or less represents a cell
35 population enriched in suppressor cells of the double negative suppressor (DNS) and/or null phenotype as

-70-

compared to unfractionated cell populations from said blood cell source, or

contains an effective amount of suppressor cells of the DNS and/or null phenotype and said population is free of sufficient number of counteracting cell phenotypes so as to retain suppressive activity of the cell population.

4. The cell population of claim 2 or 3 which further contains an effective amount of progenitor cells.

5. A method to prepare a cell population capable of suppressing the mixed lymphocyte reaction (MLR) *in vitro*, which method comprises subjecting a suspension of cells derived from a human blood cell source to a gradient separation and recovering approximately 5% or less of said population:

which are contained in the lowest density fraction of said gradient, or

which represent a cell population enriched in suppressor cells of the double negative suppressor (DNS) and/or null phenotype as compared to unfractionated cell populations from said blood cell source, or

which contain an effective amount of suppressor cells of the DNS and/or null phenotype and said population is free of sufficient number of counteracting cell phenotypes so as to retain suppressive activity of the cell population.

6. A method to prepare a population of cells capable of suppressing the mixed lymphocyte reaction (MLR) *in vitro*, which method comprises optionally subjecting a suspension of cells from a mammalian blood cell source to treatment to deplete said population of any red blood cells,

-71-

optionally subjecting said cell suspension to separation to deplete any polymorphonuclear cells and recover mononuclear cells;

optionally subjecting the mononuclear cells
5 to a plastic adherent surface to remove any monocytes;
subjecting said cell suspension to Percoll gradient separation; and

recovering the approximately 5% or less of the cells from the original blood cell source which
10 are enriched in null NS cells and/or DNS cells and depleted in T-helper cells.

7. A method to prepare a cell population consisting essentially of double negative suppressor
15 (DNS) cells or of null NS cells, which method comprises subjecting a cell suspension prepared from a mammalian blood cell source to a Percoll gradient and recovering the cells in the low density fraction of said gradient enriched for DNS cells as compared to
20 other T cells; and either

staining said cells for CD4, CD8 and TCR $\alpha\beta$;
subjecting said stained cells to flow cytometry; and

recovering the fraction corresponding to DNS
25 cells; or

staining the remaining cells of the suspension for CD4, CD16, Ig, IL-2R, CD3, CD8 and TCR $\alpha\beta$;

subjecting said stained cells to flow
30 cytometry; and

recovering the fraction corresponding to null cells.

8. A method to expand a population of DNS
35 or null suppressor cells, which method comprises treating a population enriched in DNS or null suppressor cells with at least one cytokine,

-72-

wherein the method optionally further includes treating said cells with PHA and/or ConA and/or anti CD3 antibodies.

5 9. A population of cells prepared by the method of claims 5, 6, 7 or 8.

10 10. The cell line of claim 1 or the cell population of claims 2, 3, 4 or 9 for use in preventing graft-versus-host disease.

15 11. The cell line of claim 1 or the cell population of claims 2, 3, 4 or 9 for use in enhancing engraftment of a bone marrow or organ transplant.

12. A method to prepare a population of blood cells enriched in hematopoietic CD34⁺ progenitor cells which method comprises

20 subjecting a cell population obtained from a source of mammalian blood cells to density gradient separation under physiological conditions of osmolality and pH, and

recovering from fractions of low density a fraction enriched in said progenitor cells.

25

13. The method of claim 12 wherein said recovered fraction represents 5% or less of said cells subjected to density gradient separation and having the lowest density, or

30 said density gradient is a Percoll gradient and wherein said fraction represents 40-45% Percoll, or

said recovered fraction contains at least 10% of CD34⁺ progenitor cells, or

35 said method further includes, prior to the step of subjecting said population to gradient density separation, subjecting said source of mammalian blood

-73-

cells to steps of removing red blood cells and/or polymorphonuclear cells from said population.

14. A population of cells enriched in
5 progenitor cells prepared by the method of claim 12 or 13.

15. A cell population derived from a
mammalian blood cell source which population comprises
10 at least 10% CD34⁺ cells and is substantially free of red blood cells and polymorphonuclear cells.

16. The population of claim 15 which:
is of such density so as to match the
15 density of the range of 40-45% Percoll, or
is enriched in suppressor cells of the double negative suppressor (DNS) and/or null phenotype as compared to unfractionated cell populations from said blood cell source, or
20 contains an effective amount of suppressor cells of the DNS and/or null phenotype and said population is free of sufficient number of counteracting cell phenotypes so as to retain suppressive activity of the cell population, or
25 represents less than 5% of the blood cells in said blood cell source.

17. The cell population of claim 14, 15 or 16 for use in restoring the hematopoietic progenitor
30 cell population in a subject.

18. A soluble suppressor factor (SF)
protein in purified and isolated form of approximately
20 kd monomeric molecular weight which is isolatable
35 from PMA/ionophore-treated T cells, said T cells having a DNS or null phenotype and displaying no natural killer activity against corresponding target

-74-

cells, said SF being capable of inhibiting the mixed lymphocyte reaction (MLR) but which SF does not inhibit IL-2 production in splenocyte cells stimulated by ConA, PHA or anti-CD3.

5

19. A soluble suppressor factor (SF) protein in purified and isolated form of approximately 20 kd which has the N-terminal amino acid sequence:

10 X-Glu-Asn-Val-Gly-Leu-Asn-Glu-Val-Val-(Ala/Phe)-Leu-(Lys/Leu)-Tyr-Gln-Val, and is capable of inhibiting the mixed lymphocyte reaction (MLR).

20. A method to prepare a suppressor factor (SF) protein which comprises adding to a culture of a cell line, which cell line has a DNS or a null surface phenotype suppresses the MLR and which displays no natural killer activity against corresponding target cells, an amount of PMA and calcium ionophore effective to induce the secretion of said SF into the supernatant;

20 recovering the supernatant, and optionally applying the supernatant to a DEAE-Sepharose anion-exchange column under conditions wherein said SF is adsorbed to the column; eluting said column with a salt gradient to obtain a plurality of fractions; recovering those fractions which contain said SF, or

30 applying said supernatant to a chromatography column which contains, as an affinity ligand, antibody immunoreactive with said SF under conditions wherein said SF is adsorbed to the column; and eluting said SF from the column, and

35 which method optionally further includes applying said fractions recovered from said DEAE column to a chromatography column which contains, as an affinity ligand, antibody immunoreactive with said

-75-

SF under conditions wherein said SF is adsorbed to the column; and eluting said SF from the column, or

optionally applying said recovered fractions to a lentil-lectin chromatography column under
5 conditions wherein said SF is adsorbed to the column; and eluting said SF from the column.

21. Antibodies or immunoreactive fragments thereof which are specifically immunoreactive with the
10 SF of claim 18 or 19.

22. A pharmaceutical composition suitable for conferring immunosuppression on a subject which composition comprises as active ingredient the SF
15 protein of claim 18 or 19 in admixture with a pharmaceutically acceptable excipient.

23. A composition of DNA molecules which consists of DNA molecules comprising DNA that encodes
20 the suppressor factor protein of claim 18 or 19.

24. An expression system capable, when contained in a compatible host cell, of expressing a DNA sequence encoding the SF protein of claim 18 or
25 19, said expression system comprising said SF protein-encoding DNA operably linked to control sequences capable of effecting its expression.

25. Recombinant host cells transformed or
30 transfected with the expression system of claim 24.

26. A method to produce a suppressor factor protein capable of inhibiting the mixed lymphocyte reaction (MLR) but which SF does not inhibit IL-2
35 production in splenocyte cells stimulated by ConA, PHA or anti-CD3,

-76-

which method comprises culturing the cells
of claim 25 under conditions wherein said encoding DNA
is expressed; and
recovering said SF protein from the culture.

5

10

15

20

25

30

35

1/7






FIG. 1

2/7



3/7




FIG. 3






FIG. 4

SUBSTITUTE SHEET

4/7

**FIG. 5****FIG. 6****SUBSTITUTE SHEET**

5/7




FIG. 7

6/7




FIG. 8

7/7




FIG. 9




FIG. 10

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C12N 15/19, 5/06, 5/08 A61K 35/14, 35/28, 37/02 C07K 15/06, 15/28	A3	(11) International Publication Number: WO 93/09234 (43) International Publication Date: 13 May 1993 (13.05.93)
(21) International Application Number: PCT/US92/09628 (22) International Filing Date: 5 November 1992 (05.11.92) (30) Priority data: 789,169 5 November 1991 (05.11.91) US 931,210 17 August 1992 (17.08.92) US (60) Parent Application or Grant (63) Related by Continuation US 07/931,210 (CIP) Filed on 17 August 1992 (17.08.92) (71) Applicant (for all designated States except US): THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY [US/US]; 857 Serra Street, Stanford, CA 94305 (US).		(72) Inventor; and (75) Inventor/Applicant (for US only): STROBER, Samuel [US/US]; 435 Golden Oak Drive, Portola Valley, CA 94025 (US). (74) Agents: MURASHIGE, Kate, H., et al.; MORRISON & FOERSTER, 755 Page Mill Road, Palo Alto, CA 94304-1018 (US). (81) Designated States: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, PL, RO, RU, SD, SE, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments</i> (88) Date of publication of the international search report: 5 August 1993 (05.08.93)

(54) Title: SUPPRESSOR AND PROGENITOR CELLS**(57) Abstract**

Natural suppressor (NS) cells secrete a soluble protein suppressor factor (SF) which suppresses the mixed lymphocyte response. NS cells as described herein are null, i.e., have the phenotype IL-2R⁺, CD3⁻, CD4⁻, CD8⁻, TCRαβ⁻, Ig⁻, MAC-1⁻, or are double negative suppressors (DNS); i.e., have the phenotype IL-2R⁺, CD3⁺, CD4⁻, CD8⁻, TCRαβ⁺. Both NS and SF are useful *in vivo* to confer immunotolerance with respect to allogeneic transplants, and to effect immunosuppression. They also enhance engraftment of transplanted cells. A population of cells can be provided using density gradient separation techniques which is enriched in progenitor cells as identified by the presence of CD34 surface markers.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 92/09628

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC		
Int.C1.5	C 12 N 15/19	C 12 N 5/06
A 61 K 35/14	A 61 K 35/28	A 61 K 37/02
C 07 K 15/28		C 07 K 15/06
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
Int.C1.5	C 12 N	C 07 K A 61 K
Documentation Searched other than Minimum Documentation to the extent that such Documents are included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹		
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
X	JOURNAL OF IMMUNOLOGY vol. 143, no. 4, 15 August 1989, BALTIMORE US pages 1118 - 1122 STROBER, S. ET AL. 'Cloned natural suppressor cell lines express CD3+CD4-CD8 surface phenotype and the alpha,beta heterodimer of the T cell antigen receptor' cited in the application see the whole document ---	1,10-11
X	CELLULAR IMMUNOLOGY vol. 136, no. 1, August 1991, NEW YORK, US pages 1 - 15 VAN VLASSELAER, P. ET AL. 'Regulation of thymocyte proliferation by alpha beta TcR+ CD3+ CD4- CD8- cloned natural suppressor (NS) cells' cited in the application see the whole document --- -/-	1,10-11
<div style="display: flex; justify-content: space-between;"> <div style="width: 48%;"> <p>¹⁰ Special categories of cited documents :</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 48%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p> </div> </div>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
03-03-1993	13. 07. 93	
International Searching Authority	Signature of Authorized Officer	
EUROPEAN PATENT OFFICE	S.-M. ANDRES	

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category °	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
X	EP,A,0249502 (THE BOARD OF TRUSTEES OF THE LELAND STANFORD JR. UNIVERSITY) 16 December 1987 see the whole document ---	1,10-11
A	JOURNAL OF IMMUNOLOGY vol. 133, no. 5, November 1984, BALTIMORE US pages 2791 - 2796 HERTEL-WULFF, B. ET AL. 'In vitro propagation and cloning of murine natural suppressor (NS) cells' cited in the application see the whole document ---	1,10-11
A	JOURNAL OF IMMUNOLOGY vol. 138, no. 3, 1 February 1987, BALTIMORE US pages 699 - 703 STROBER, S. ET AL. 'Cloned natural suppressor cells prevent lethal graft-vs-host disease' cited in the application see the whole document ---	1,10-11
P,X	JOURNAL OF IMMUNOLOGY vol. 148, no. 2, 15 January 1992, BALTIMORE US pages 373 - 380 PALATHUMPAT, V. ET AL. 'Studies of CD4-CD8- alpha,beta bone marrow T cells with suppressor activity' cited in the application see the whole document ---	1,10-11
T	BLOOD vol. 80, no. 12, 15 December 1992, NEW YORK, USA pages 3242 - 3250 SCHMIDT-WOLF, I. ET AL. 'T-cell subsets and suppressor cells in human bone marrow' -----	

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 92/09628

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos. because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos. because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos. because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see PCT/ISA/206 mailed on 21.04.93

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1 and partially 10-11

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees

US 9209628
SA 67238

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 23/06/93. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A- 0249502	16-12-87	AU-A- 7412987 JP-A- 63039899	17-12-87 20-02-88
